

INDEPENDENT AUDITOR'S REPORT

To the shareholders of TERAPIA SA

Address: 124, FABRICII STR., CLUJ NAPOCA, ROMANIA, CUI 15357398

Opinion

1. We have audited the financial statements of TERAPIA SA ("the Company"), which comprise the balance sheet as at March 31, 2025, and the profit and loss statement, statement of changes in equity and cash flow statement for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.
2. The afore mentioned financial statements refer to:
 - Net assets/Total equity and reserves: 1.235.126.338 lei
 - Net result of the year (profit): 344.949.081 lei
3. In our opinion the accompanying financial statements present fairly, in all material respects, the financial position of the Company as at March 31, 2025, and its financial performance and its cash flows for the year then ended in accordance with the Order of the Minister of Public Finance no. 1802/2014, with subsequent amendments (" OMFP 1802/2014").

Basis for opinion

4. We conducted our audit in accordance with the International Standards on Auditing (ISA) and Law 162/2017 (" the Law"). Our responsibilities under those standards are further described in the " Auditors' Responsibilities for the Audit of the Financial Statements" section of our report. We are independent of the Company in accordance with the Code of Ethics for the Professional Accountants issued by the International Ethics Standards Board for Accountants, in accordance with the ethical requirements that are relevant to our audit of the financial statements in Romania, including the Law and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other aspects

5. This report of the independent auditor is addressed exclusively to the Shareholders of the Company as a whole. Our audit was conducted in order to be able to report to the shareholders of the Company those aspects that we must report in a financial audit report, and not for other purposes. To extent permitted by law, we do not accept and assume no responsibility except to the Company and its shareholders, as a whole, for our audit, for this report or for the opinion formed.

Other Information - Administrator's Report

6. The administrators are responsible for preparation and presentation of other information. The other information comprises the Administrator's Report but does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

With regards to the Administrator's Report, we have read and report whether it was prepared, in all material respects, in accordance with the OMFP 1802/2014, articles 489-492.

Based exclusively on the activities that should be done during the audit of the financial statements, in our opinion:

- a) Information presented in the Administrators' Report for the financial period for which the financial statements have been prepared, is in accordance, in all material respects, with financial statements;
- b) The Administrators' Report has been prepared, in all material respects, in accordance with OMFP 1802/2014, articles 489-492.

Besides this, based on our knowledge and understanding of the Company and its environment gained during the audit of financial statements for the year ended at 31 March 2025, we shall report whether we identified any information included into Administrators' Report that is material misstated. We have nothing to report in this regard.

Responsibilities of Management and Those charged with Governance for the Financial Statements

7. Management is responsible for the preparation of the financial statements in accordance with OMFP 1802/2014, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error
8. In preparing the financial statements, management is responsible for assessing the Company's ability to continue as going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management intends to liquidate the Company's or to cease operations, or has no realistic alternative but to do so.
9. Those charged with governance are responsible for overseeing the Company's financial reporting process

Auditors' Responsibilities for the Audit of the Financial Statements

10. Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decision of users taken on the basis of these financial statements.
11. As part of an audit in accordance with the audit standards adopted by the Romanian Chamber of Financial Auditors, which are based on International Standards on Auditing, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
 - a) Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;
 - b) Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control;
 - c) Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management;
 - d) Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern;
 - e) Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.



12. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

On behalf of:

BDO Audit SRL

Authorized by the Authority for Public Supervision of Statutory Audit Activity (ASPAAS)
Under FA18

Bogdan Nistorescu, Engagement partner

Authorized by the Authority for Public Supervision of Statutory Audit Activity (ASPAAS)
Under AF4304

Cluj Napoca, Romania

May, 13th 2025

For stamp and signature please refer to the Romanian original version

S.C. TERAPIA S.A.

FINANCIAL STATEMENTS

Prepared in accordance with
the Order of the Ministry of Public Finance no. 1802/2014
with subsequent amendments

31 MARCH 2025

TABLE OF CONTENTS

| | |
|---|--------------|
| Balance sheet | 3-6 |
| Profit and loss account..... | 7-9 |
| Cash flow..... | 10 |
| Statement of Changes in Equity..... | 11-12 |
| Notes to the Financial Statements..... | 13-50 |

S.C. TERAPIA S.A.
BALANCE SHEET
For the year ended 31 March 2025
(all amounts are expressed in RON, unless specified otherwise)

Balance sheet as of 31 March 2025
(in accordance with OMF 1802/2014)

| Element name | Row no. | Balance as of | |
|---|-----------|--------------------------------------|--------------------------------|
| | | The beginning of the year 01.04.2024 | The end of the year 31.03.2025 |
| A | B | 1 | 2 |
| A. NON-CURRENT ASSETS | | | |
| I. INTANGIBLE ASSETS | | | |
| 1. Set-up costs (account 201-2801) | 01 | | |
| 2. Development costs (account 203-2803-2903) | 02 | | |
| 3. Concessions, patents, licenses, trademarks, similar rights and assets and other intangible assets (account 205+208-2805-2808-2905-2908) | 03 | 104,262,530 | 619,655,169 |
| 4. Goodwill (account 2071-2807) | 04 | | |
| 5. Intangible assets for exploration and evaluation of mineral resources (account 206-2806-2906) | 05 | | |
| 6. Advance payments (account 4094) | 06 | | |
| TOTAL: (row 01 to 06) | 07 | 104,262,530 | 619,655,169 |
| II. TANGIBLE ASSETS | | | |
| 1. Freehold land and buildings (account 211+212-2811-2812-2911-2912) | 08 | 189,874,480 | 205,734,591 |
| 2. Plant and machinery (account 213+223--2813-2913) | 09 | 25,284,156 | 27,910,195 |
| 3. Other plant, machinery and fixtures (account 214+224-2814-2914) | 10 | 2,837,650 | 3,449,416 |
| 4. Real estate investments (account 215-2815-2915) | 11 | | |
| 5. Tangible fixed assets in progress (account 231-2931) | 12 | 21,162,860 | 6,261,046 |
| 6. Real estate investments in progress (account 235-2935) | 13 | | |
| 7. Tangible assets for exploration and evaluation of mineral resources (account 216-2816-2916) | 14 | | |
| 8. Productive biological assets (account 217+227-2817-2917) | 15 | | |
| 4. Advance payments (account 4093) | 16 | 1,462,872 | 9,597,454 |
| TOTAL: (row 08 to 16) | 17 | 240,622,018 | 252,952,702 |
| III. LONG-TERM FINANCIAL INVESTMENTS | | | |
| 1. Investments in subsidiaries (account 261-2961) | 18 | | |
| 2. Loans to subsidiaries (account 2671+2672-2964) | 19 | | |
| 3. Investments in associates and jointly controlled entities (account 262+263-2962) | 20 | | |
| 4. Loans granted to entities related to the company on the grounds of investments in associates and jointly controlled (account 2673 + 2674 - 2965) | 21 | | |
| 5. Investments owned as assets (account 265+266-2963) | 22 | | |
| 6. Other loans (account 2675+2676+2677+2678+2679-2966-2968) | 23 | 72,560 | 72,563 |
| TOTAL: (row 18 to 23) | 24 | 72,560 | 72,563 |
| TOTAL NON-CURRENT ASSETS (row 07+17+24) | 25 | 344,957,108 | 872,680,434 |
| B. CURRENT ASSETS | | | |
| I. INVENTORIES | | | |
| 1. Raw materials and consumables (account 301+321+302+322+303+323 +/-308+351+358+381+328+/-388-391-392-3951-3958-398) | 26 | 28,673,595 | 27,233,685 |
| 2. Work in progress (account 331+332+341+/-348-393-3941-3952) | 27 | 3,948,628 | 2,367,553 |

S.C. TERAPIA S.A.
BALANCE SHEET
For the year ended 31 March 2025
(all amounts are expressed in RON, unless specified otherwise)

| Element name | Row no. | Balance as of | |
|---|-----------|---|-----------------------------------|
| | | The beginning of the year 01.04.2024 | The end of the year 31.03.2025 |
| A | B | 1 | 2 |
| 3. Finished goods and merchandise (account 345+346+/-348+354+356+357 +361+326+/-368+371+327+/-378-3945-3946-3953-3954-3956-3957-396-397-4428) | 28 | 121,784,972 | 100,283,466 |
| 4. Advance payments for the acquisition of inventories (account 4091) | 29 | 1,077,697 | 5,627,397 |
| TOTAL (row 26 to 29) | 30 | 155,484,892 | 135,512,101 |
| II. RECEIVABLES | | | |
| 1. Trade receivables (account 2675+2676+2678+2679-2966-2968+4092+411+413 +418-491) | 31 | 487,146,366 | 581,364,451 |
| 2. Receivables from non-consolidated associated companies (account 451-495) | 32 | 73,243,510 | 33,964,080 |
| 3. Receivables from other equity investments (account 453-495) | 33 | | |
| 4. Other receivables (account 425+4282+431+437+4382+441+4424+4428+444+445+446+447+4482+4582+461+473-496+5187) | 34 | 18,456,398 | 19,505,576 |
| 5. Subscribed and not paid in share capital (account 456-495) | 35 | | |
| Receivables representing dividends distributed during the financial year (account 463) | 35a | | |
| TOTAL (row 31 to 35) | 36 | 578,846,274 | 634,834,107 |
| III. SHORT TERM INVESTMENTS | | | |
| 1. Investments in subsidiaries (account 501-591) | 37 | | |
| 2. Other short term investments (account 505+506+508-595-596-598+5113+5114) | 38 | 234,352,760 | 11,424,719 |
| TOTAL (row 37 to 38) | 39 | 234,352,760 | 11,424,719 |
| IV. PETTY CASH AND BANK ACCOUNT BALANCES (account 5112+512+531+532+541+542) | 40 | 13,034,878 | 24,655,573 |
| CURRENT ASSETS - TOTAL (row 30+36+39+40) | 41 | 981,718,804 | 806,426,500 |
| C. ACCRUED EXPENSES (account 471) (row 43+44) | 42 | 1,067,329 | 1,189,991 |
| Amounts taken over a period of up to 1 year | 43 | 1,067,329 | 1,189,991 |
| Amounts taken over a period of more than 1 year | 44 | | |
| D. LIABILITIES: AMOUNTS DUE WITHIN ONE YEAR | | | |
| 1. Debenture loans (account 161+1681-169) | 45 | | |
| 2. Amounts owed to credit institutions (account 1621+1622+1624+1625+1627+1682+5191+5192+ 5198) | 46 | | |
| 3. Advance payments received for orders (account 419) | 47 | 45,005 | 75,687 |
| 4. Trade debts – suppliers (account 401+404+408) | 48 | 106,640,220 | 288,694,586 |
| 5. Bills of exchange payable (account 403+405) | 49 | | |
| 6. Amounts due to non-consolidated associated companies (account 1661+1685+2691+451) | 50 | 75,149,849 | 32,556,772 |
| 7. Amounts due to other equity investments (account 1663+1686+2692+453) | 51 | | |
| 8. Other liabilities, including tax and social security contributions liabilities (account 1623+1626+167+1687+2695+421+423+424+426+427+ 4281+431+436 +437+4381+441+4423+4428+444+446+447+4481+455+456+457+4581 +462+4661+467+473+509+5186+5193+5194+5195+5196+5197) | 52 | 85,781,399 | 104,775,355 |
| TOTAL: (row 45 to 52) | 53 | 267,616,473 | 426,102,400 |

S.C. TERAPIA S.A.
BALANCE SHEET
For the year ended 31 March 2025
(all amounts are expressed in RON, unless specified otherwise)

| Element name | Row no. | Balance as of | |
|---|-----------|---|-----------------------------------|
| | | The beginning of the year 01.04.2024 | The end of the year 31.03.2025 |
| A | B | 1 | 2 |
| E. NET CURRENT ASSETS/NET CURRENT LIABILITIES (row 41+43-53-70-73-76) | 54 | 714,277,700 | 380,622,339 |
| F. TOTAL ASSETS LESS CURRENT LIABILITIES (row 25+44+54) | 55 | 1,059,234,808 | 1,253,302,773 |
| G. LIABILITIES: AMOUNTS DUE AFTER ONE YEAR | | | |
| 1. Debenture loans (account 161+1681-169) | 56 | | |
| 2. Amounts payable to credit institutions (account 1621+1622+1624+1625+1627+1682+5191+5192+5198) | 57 | | |
| 3. Advance payments received for orders (account 419) | 58 | | |
| 4. Trade debts – suppliers (account 401+404+408) | 59 | | |
| 5. Bills of exchange payable (account 403+405) | 60 | | |
| 6. Amounts due to non-consolidated associated companies (account 1661+1685+2691+451) | 61 | | |
| 7. Amounts due to other equity investments (account 1663+1686+2692+453) | 62 | | |
| 8. Other liabilities, including tax and social security contributions liabilities (account 1623+1626+167+1687+2695+421+423+424+426+427+ 4281+431+436 +437+4381+441+4423+4428+444+446+447+4481+455+456+457+4581 +462+4661+467+473+509+5186+5193+5194+5195+5196+5197) | 63 | | |
| TOTAL (row 56 to 63) | 64 | | |
| H. ACCRUED LIABILITIES | | | |
| 1. Accrued for employee benefits (account 1515+1517) | 65 | 5,337,907 | 5,788,957 |
| 2. Accrued taxes payable (account 1516) | 66 | 9,103,205 | 8,623,180 |
| 3. Other accrued liabilities and provisions (account 1511+1512+1513+1514+1518) | 67 | 230,690 | 230,690 |
| TOTAL ACCRUED LIABILITIES & PROVISIONS (row 65 to 67) | 68 | 14,671,802 | 14,642,827 |
| I. DEFERRED INCOME | | | |
| 1. Investment subsidies (account 475) (row 70+71) | 69 | 5,317,320 | 4,425,360 |
| Amounts to be retaken in a period under a year (account 475) | 70 | 891,960 | 891,752 |
| Amounts to be retaken in a period over a year (account 475) | 71 | 4,425,360 | 3,533,608 |
| 2. Deferred income (account 472) - total (row 73+74) of which: | 72 | | |
| Amounts to be retaken in a period under a year (account 472) | 73 | | |
| Amounts to be retaken in a period over a year (account 472) | 74 | | |
| 3. Deferred income related to assets received from customers transfer (ct.478) (row 76+77) | 75 | | |
| Amounts to be retaken in a period under a year (account 478) | 76 | | |
| Amounts to be retaken in a period over a year (account 478) | 77 | | |
| Negative goodwill (account 2075) | 78 | | |
| TOTAL (row 69+72+75+78) | 79 | 5,317,320 | 4,425,360 |
| J. CAPITAL AND RESERVES | | | |
| I. CAPITAL | | | |
| 1. Subscribed and paid in capital (account 1012) | 80 | 24,993,398 | 24,993,398 |
| 2. Subscribed and not paid in capital (account 1011) | 81 | | |
| 3. Patrimony (autonomous companies) (account 1015) | 82 | | |

S.C. TERAPIA S.A.
BALANCE SHEET
For the year ended 31 March 2025
(all amounts are expressed in RON, unless specified otherwise)

| Element name | Row no. | Balance as of | |
|---|------------------|---|-----------------------------------|
| | | The beginning of the year 01.04.2024 | The end of the year 31.03.2025 |
| A | B | 1 | 2 |
| 4. Patrimony of national research and development institutes (account 1018) | 83 | | |
| 5. Other equity (account 1031) | 84 | | |
| TOTAL (row 80 to 84) | 85 | 24,993,398 | 24,993,398 |
| II. PREMIUMS RELATED TO CAPITAL (account 104) | 86 | 372,839 | 372,839 |
| III. REVALUATION RESERVE (account 105) | 87 | 164,790,099 | 161,266,915 |
| IV. OTHER RESERVES | | | |
| 1. Legal reserve (account 1061) | 88 | 8,617,940 | 8,617,940 |
| 2. Statutory or contractual capital reserve (account 1063) | 89 | | |
| 3. Other reserves (account 1068) | 90 | 38,118,381 | 38,118,381 |
| TOTAL (row 88 to 90) | 91 | 46,736,321 | 46,736,321 |
| Own shares (account 109) | 92 | | |
| Gains on own equity instruments (account 141) | 93 | | |
| Losses on own equity instruments (account 149) | 94 | 782,785 | 782,785 |
| V. PROFIT / (LOSS) BROUGHT FORWARD (account 117) | Balance C | 95 | 504,350,288 |
| | Balance D | 96 | 657,590,569 |
| VI. PROFIT / (LOSS) FOR THE YEAR (account 121) | Balance C | 97 | 299,677,486 |
| | Balance D | 98 | 344,949,081 |
| Profit appropriation (account 129) | 99 | | |
| TOTAL EQUITY (row 85+86+87+91-92+93-94+95-96+97-98-99) | 100 | 1,040,137,646 | 1,235,126,338 |
| Public patrimony (account 1016) | 101 | | |
| Private patrimony (account 1017) | 102 | | |
| TOTAL CAPITAL (row 100+101+102) (row 25+41+42-53-64-68-79) | 103 | 1,040,137,646 | 1,235,126,338 |

ADMINISTRATOR,
Dragoş Eugen Damian

ECONOMIC DIRECTOR,
Bucur Paul Cosmin

S.C. TERAPIA S.A.
PROFIT AND LOSS ACCOUNT
For the year ended 31 March 2025
(all amounts are expressed in RON, unless specified otherwise)

Profit and loss account for the year ended 31 March 2025
(in accordance to OMF 1802/2014)

| INDICES | Row no. | Financial year | |
|--|-----------|----------------------|----------------------|
| | | Previous | Current |
| A | B | 1 | 2 |
| 1.Net turnover (row 02 +03-04+ 05+06) | 01 | 1,271,280,392 | 1,419,608,363 |
| - of which, the net turnover of the predominant activity actually carried out | 01a | 1,243,799,489 | 1,387,799,860 |
| - of which, the net turnover of the operations on the national territory | 01b | 963,582,015 | 1,135,321,776 |
| Sales of produced goods (account 701+702+703+704+705+706+708) | 02 | 732,009,604 | 800,326,276 |
| Sales of goods purchased for resale (account 707) | 03 | 930,464,756 | 1,148,013,172 |
| Trade discounts granted (account 709) | 04 | 391,193,968 | 528,731,085 |
| Interest income of entities cancelled from the General Register and which have leasing contracts in progress (account 766) | 05 | | |
| Subsidies related to the net turnover (account 7411) | 06 | | |
| 2.Inventories variation (account 711+712) Balance C | 07 | | 2,091,954 |
| Balance D | 08 | 978,873 | |
| 3.Own production capitalized (account 721+722) | 09 | | |
| 4.Income from revaluation of tangible assets (account 755) | 10 | 111,307 | 206 |
| 5.Real estate investments production income (account 725) | 11 | | |
| 6.Income from subsidies (account 7412+7413+7414+7415+7416+7417+7419) | 12 | | |
| 7.Other operating income (account 751+758+7815) | 13 | 3,617,515 | 1,783,041 |
| - out of which income from negative goodwill (acc.7815) | 14 | | |
| - out of which income from investment subsidies (acc.7584) | 15 | 801,839 | 891,960 |
| TOTAL OPERATING REVENUES (row 01+07-08+09+10+11+12+13) | 16 | 1,274,030,341 | 1,423,483,564 |
| 8.a) Expenses related to raw materials and consumables (account 601+602) | 17 | 89,360,210 | 90,205,849 |
| Other material expenses (account 603+604+606+608) | 18 | 4,950,759 | 5,304,207 |
| b) Other utilities expenses (electricity, heating and water) (account 605-7413) | 19 | 11,400,834 | 11,908,122 |
| - of which, expenditure on energy consumption (ct. 6051) | 19a | 8,052,583 | 8,242,361 |
| - of which, expenditure on natural gas consumption (ct. 6053) | 19b | 2,934,776 | 3,201,479 |
| Expenses regarding goods for resale (account 607) | 20 | 322,090,058 | 360,830,561 |
| Trade discounts received (account 609) | 21 | 680,305 | 5,224,816 |
| 9.Personnel expenses (row 23+24) | 22 | 150,798,295 | 166,782,212 |
| a) Salaries (account 641+642+643+644) | 23 | 147,692,316 | 163,256,126 |
| b) Expenses related to social security contributions (account 645+646) | 24 | 3,105,979 | 3,526,086 |
| 10.a) Value adjustment related to tangible and intangible assets (row 26a+26-27) | 25 | 43,049,945 | 25,606,457 |
| a.1) Expenses for assets depreciation and amortization (account 6811) | 26a | 42,931,259 | 25,527,874 |
| a.2) Expenses (account 6813+6817+from acc.6818) | 26 | 118,686 | 78,583 |
| a.3) Revenues (account 7813+from acc.7818) | 27 | | |
| b) Value adjustment for current assets (row 29-30) | 28 | 5,046,831 | 12,819,302 |
| b.1) Expenses (account 654+6814+from acc.6818) | 29 | 15,240,376 | 22,926,704 |
| b.2) Revenues (account 754+7814+from acc.7818) | 30 | 10,193,545 | 10,107,402 |
| 11.Other operating expenses (row 32+33+33d+33f+33h+33j+34+35+36+37) | 31 | 307,785,325 | 361,941,160 |

S.C. TERAPIA S.A.
PROFIT AND LOSS ACCOUNT
For the year ended 31 March 2025
(all amounts are expressed in RON, unless specified otherwise)

| INDICES | Row no. | Financial year | |
|--|-----------|--------------------|----------------------|
| | | Previous | Current |
| A | B | 1 | 2 |
| 11.1. Third party services expenses (account 611+613+614+615+621+622+623+624+625+626+627+628) | 32 | 195,365,443 | 233,963,550 |
| 11.2. Expenses with royalties, administrativ locations and rents (ct. 612), of which: | 33 | 9,388,763 | 10,937,570 |
| -expenses with royalties (account 6121) | 33a | | |
| -expenses with administrativ locations (account 6122) | 33b | | |
| -expenses with rents (account 6123) | 33c | 9,388,763 | 10,937,570 |
| 11.3. Expenses related to intellectual property rights (acc. 616), of which: | 33d | 134,105 | 135,769 |
| -expenses in the relationship with affiliated entities | 33e | | |
| 11.4. Management expenses (account 617), of which: | 33f | | 865,245 |
| -expenses in the relationship with affiliated entities | 33g | | |
| 11.5. Consulting expenses (account 618), of which: | 33h | 178,426 | 150,239 |
| -expenses in the relationship with affiliated entities | 33i | | |
| 11.6 Other taxes, duties and similar expenses (account 635+6586) | 33j | 73,492,754 | 83,155,396 |
| 11.7 Compensations, gifts and assets disposed (account 652) | 34 | 923,549 | 1,112,428 |
| 11.8 Expenses from revaluation of tangible assets (account 655) | 35 | 53,346 | |
| 11.9 Expenses related to calamities and other similar events (account 6587) | 36 | | |
| 11.10 Other expenses (account 651+6581+6582+6583+6588) | 37 | 28,248,939 | 31,620,963 |
| Expenses related to refinancing interests of entities cancelled from the General Register and which still have leasing contracts in progress (ac. 666) | 38 | | |
| 12.Adjustments related to provisions (rd.40-41) | 39 | 2,649,654 | (28,975) |
| Expenses (account 6812) | 40 | 3,188,227 | 836,829 |
| Revenues (account 7812) | 41 | 538,573 | 865,804 |
| TOTAL OPERATING EXPENSES (row 17 to 20- 21+22+25+25+31+39) | 42 | 936,451,606 | 1,030,144,079 |
| OPERATING PROFIT OR LOSS: | | | |
| Profit (row 16-42) | 43 | 337,578,735 | 393,339,485 |
| Loss (row 42-16) | 44 | | |
| 13.Revenues from investments (account 7611+7612+7613) | 45 | | |
| - from which, income earned from affiliated entities | 46 | | |
| 14.Interest income (account 766) | 47 | 9,861,318 | 10,052,854 |
| - from which, income from associates | 48 | | |
| 15.Revenues from subsidies for interest due (account 7418) | 49 | | |
| 16.Other financial income (account 762+764+765+767+768) | 50 | 42,625,088 | 11,848,821 |
| - from which, income from other financial assets | 51 | | |
| TOTAL FINANCIAL REVENUES (ROW 45+47+49+50) | 52 | 52,486,406 | 21,901,675 |
| 17. Value adjustments regarding financial assets and current asset investments (row 54-55) | 53 | | |
| - expenses (account 686) | 54 | | |
| - income (account 786) | 55 | | |
| 18.Interest expense (account 666) | 56 | | 96,115 |
| - from which, expenses related to associated companies | 57 | | |
| 19.Other financial expenses (account 663+664+665+667+668) | 58 | 46,905,396 | 9,407,447 |
| TOTAL FINANCIAL EXPENSES (row 53+56+58) | 59 | 46,905,396 | 9,503,562 |
| FINANCIAL PROFIT OR LOSS | | | |
| Profit (row 52-59) | 60 | 5,581,010 | 12,398,113 |
| Loss (row 59-52) | 61 | | |

S.C. TERAPIA S.A.
PROFIT AND LOSS ACCOUNT
For the year ended 31 March 2025
(all amounts are expressed in RON, unless specified otherwise)

| INDICES | Row no. | Financial year | |
|--|-----------|----------------------|----------------------|
| | | Previous | Current |
| A | B | 1 | 2 |
| TOTAL REVENUES (row 16+52) | 62 | 1,326,516,747 | 1,445,385,239 |
| TOTAL EXPENSES (row 42+59) | 63 | 983,357,002 | 1,039,647,641 |
| PROFIT OR LOSS BEFORE TAX | | | |
| Profit (row 62-63) | 64 | 343,159,745 | 405,737,598 |
| Loss (row 63-62) | 65 | | |
| 20.INCOME TAX (account 691) | 66 | 43,482,259 | 56,068,095 |
| 21.Expenses with income tax resulting from settlement within the fiscal group in the field of income tax (account 694) | 66a | | |
| 22.Income with income tax resulting from settlement within the fiscal group in the field of income tax (account 794) | 66b | | |
| 23.Taxes specific to certain activities (695) | 67 | | |
| 24.Other tax expenses not included above (account 698) | 68 | | 4,720,422 |
| NET PROFIT OR LOSS FOR THE YEAR | | | |
| Profit (row 64-65-66-67-68-66a+66b) | 69 | 299,677,486 | 344,949,081 |
| Loss (row 65+66+67+68-64+66a-66b) | 70 | | |

ADMINISTRATOR,

Dragoş Eugen Damian

ECONOMIC DIRECTOR,

Bucur Paul Cosmin

S.C. TERAPIA S.A.
CASH FLOW STATEMENT
for the year ended 31 March 2025
(all amounts are expressed in RON, unless specified otherwise)

Cash flow Statement
for the year ended 31 March 2025

| | 12 month period ended at 31.03.2024 | 12 month period ended at 31.03.2025 |
|--|--|--|
| OPERATING ACTIVITIES | | |
| Net profit before taxation and extraordinary items | 343,159,745 | 405,737,598 |
| Adjustments for: | | |
| Loss / profit on disposal of fixed assets | 982,795 | (8,882) |
| Impairment, depreciation and amortization | 42,931,259 | 25,527,874 |
| Movement in provisions for fixed assets | 60,725 | 78,377 |
| Movements in provisions | 2,649,554 | (28,875) |
| Net loss/profit from interest | (9,861,318) | (9,956,739) |
| Movements in provision for current assets | 5,046,831 | 12,819,302 |
| Income from subsidies | (801,839) | (891,960) |
| (Income)/losses from financial investments | | (611,065) |
| Operating profit before changes in working capital | 384,167,752 | 432,665,630 |
| Decrease/(Increase) in trade and other receivables | (99,428,857) | (56,139,713) |
| Decrease/(Increase) in inventories | (31,941,173) | 7,182,603 |
| (Decrease) / Increase in trade and other liabilities | 31,299,695 | (37,570,372) |
| Interest paid | | (96,115) |
| Corporate income tax paid | (43,052,874) | (53,953,643) |
| Cash generated from operating activities | 241,044,544 | 292,088,391 |
| INVESTMENT ACTIVITIES | | |
| Payments for the acquisition of tangible and intangibles assets | (25,785,901) | (367,959,292) |
| Proceeds from the disposal of fixed assets | 110,280 | 8,882 |
| Payments for the acquisition of short-term financial investments | (79,666,760) | |
| Proceeds from the sale of short-term financial investments | | 223,539,106 |
| Interest received | 7,300,783 | 10,052,854 |
| Cash generated from investing activities | (98,041,598) | (134,358,451) |
| FINANCING ACTIVITIES | | |
| Loan repayment | | |
| Loans received | | |
| Dividends paid | (136,513,908) | (146,109,245) |
| Cash generated from financing activities | (136,513,908) | (146,109,245) |
| Increase / (decrease) in cash and cash equivalent | 6,489,038 | 11,620,695 |
| Cash and cash equivalent at 1 April 2024 | 6,545,840 | 13,034,878 |
| Cash and cash equivalents at 31 March 2025 | 13,034,878 | 24,655,573 |

ADMINISTRATOR,
Dragoş Eugen Damian

ECOMOMIC DIRECTOR,
Bucur Paul Cosmin

S.C. TERAPIA S.A.
STATEMENT OF CHANGES IN EQUITY
for the year ended 31 March 2025
(all amounts are expressed in RON, unless specified otherwise)

Statement of Changes in Equity
for the year ended 31 March 2025

| Elements of shareholders' equity | | Balance as at 01.04.2024 | Increase | | Decrease | | Balance as at 31.03.2025 |
|--|------------|--------------------------------|------------------------|--------------------|------------------------|--------------------|--------------------------------|
| | | | TOTAL, out of which | From transfer | TOTAL, out of which | From transfer | |
| 0 | | 1 | 2 | 3 | 4 | 5 | 6 |
| Share capital | | 24,993,398 | | | | | 24,993,398 |
| Share premium | | 372,839 | | | | | 372,840 |
| Revaluation reserve | | 164,790,099 | | | 3,523,184 | 3,523,184 | 161,266,913 |
| Legal reserve | | 8,617,940 | | | | | 8,617,940 |
| Other reserves | | 38,118,381 | | | | | 38,118,381 |
| Retained earnings representing undistributed accumulated profit or accumulated losses | Cr Balance | 438,597,680 | 299,677,486 | 299,677,486 | 149,960,389 | | 588,314,777 |
| | Dr Balance | | | | | | |
| Effect of first time adoption of IFRS, except for IAS 29 | Cr Balance | 5,935,237 | | | | | 5,935,237 |
| | Dr Balance | | | | | | |
| Retained result from correction of accounting errors | Cr Balance | 664,609 | | | | | 664,609 |
| | Dr Balance | | | | | | |
| Retained result representing the revaluation reserve surplus | Cr Balance | 63,934,076 | 3,523,184 | 3,523,184 | | | 67,457,260 |
| | Dr Balance | | | | | | |
| Retained result from the application of accounting regulations according to the forth Directive of the European Commission | Cr Balance | | | | | | |
| | Dr Balance | 4,781,313 | | | | | 4,781,313 |
| Profit or loss for the year | Cr Balance | 299,677,486 | 344,949,081 | | 299,677,486 | 299,677,486 | 344,949,081 |
| | Dr Balance | | | | | | |
| Profit distribution | | | | | | | |
| Other losses related to equity instruments | Cr Balance | | | | | | |
| | Dr Balance | 782,785 | | | | | 782,785 |
| TOTAL | | 1,040,137,646 | 648,149,751 | 303,200,670 | 453,161,059 | 303,200,670 | 1,235,126,338 |

Equity amounting to RON 1,235,126,338 at 31.03.2025, has increased comparated with 2024 financia year with the amount of RON 194,988,692. This evolution is due to:

- the net profit of the year amounting to RON 344,949,081;
- decrease as a result of the distribution of dividends in the amount of RON 149,960,389;

S.C. TERAPIA S.A.
STATEMENT OF CHANGES IN EQUITY
for the year ended 31 March 2025
(all amounts are expressed in RON, unless specified otherwise)

Statement of Changes in Equity
for the year ended 31 March 2024

| Elements of shareholders' equity | | Balance as at 01.04.2023 | Increase | | Decrease | | Balance as at 31.03.2024 |
|--|------------|--------------------------|---------------------|--------------------|---------------------|--------------------|--------------------------|
| | | | TOTAL, out of which | From transfer | TOTAL, out of which | From transfer | |
| 0 | | 1 | 2 | 3 | 4 | 5 | 6 |
| Share capital | | 24,993,398 | | | | | 24,993,398 |
| Share premium | | 372,839 | | | | | 372,839 |
| Revaluation reserve | | 133,104,610 | 33,585,918 | | 1,990,427 | 1,900,427 | 164,790,099 |
| Legal reserve | | 8,617,940 | | | | | 8,617,940 |
| Other reserves | | 38,118,381 | | | | | 38,118,381 |
| Retained earnings representing undistributed accumulated profit or accumulated losses | Cr Balance | 320,932,739 | 257,627,969 | 257,627,969 | 139,963,029 | | 438,597,680 |
| | Dr Balance | | | | | | |
| Effect of first time adoption of IFRS, except for IAS 29 | Cr Balance | 5,935,237 | | | | | 5,935,237 |
| | Dr Balance | | | | | | |
| Retained result from correction of accounting errors | Cr Balance | 664,609 | | | | | 664,609 |
| | Dr Balance | | | | | | |
| Retained result representing the revaluation reserve surplus | Cr Balance | 62,033,649 | 1,900,427 | 1,900,427 | | | 63,934,076 |
| | Dr Balance | | | | | | |
| Retained result from the application of accounting regulations according to the forth Directive of the European Commission | Cr Balance | | | | | | |
| | Dr Balance | 4,781,313 | | | | | 4,781,313 |
| Profit or loss for the year | Cr Balance | 257,627,969 | 299,677,486 | | 257,627,969 | 257,627,969 | 299,677,486 |
| | Dr Balance | | | | | | |
| Profit distribution | | | | | | | |
| Other losses related to equity instruments | Cr Balance | | | | | | |
| | Dr Balance | 782,785 | | | | | 782,785 |
| TOTAL | | 846,837,273 | 592,791,800 | 259,528,396 | 399,491,427 | 259,528,396 | 1,040,137,646 |

Equity amounting to RON 1,040,137,646 at 31.03.2024, has increased compared with 2023 financial year with the amount of RON 193,300,373. This evolution is due to:

- the net profit of the year amounting to RON 299,677,486;
- decrease as a result of the distribution of dividends in the amount of RON 139,963,029
- increase of the revaluation reserve with the amount of RON 33,585,918, as a result of the revaluation of tangible assets on 31.03.2024.

ADMINISTRATOR,
Dragoş Eugen Damian

ECONOMIC DIRECTOR,
Bucur Paul Cosmin

Notes to the financial statements as of 31.03.2025

These financial statements were prepared by SC Terapia SA (the “Company”) for the year ended the 31 March 2025. These financial statements were prepared in accordance with the Law on Accounting no. 82/1991 republished, the Order of the Ministry of Public Finance no. 1802/2014 for approving the accounting regulations regarding the individual and consolidated annual financial statements („OMFP 1802/2014”).

For conformity, the references to the Order 1802/2014 have to be understood as comprising its subsequent amendments introduced by normative regulations of the Ministry of Public Finance.

SC Terapia SA opted for a financial year different than the calendar year, the financial year starts on 1 April and ends on 31 March.

These financial statements of SC Terapia SA are prepared for a financial year different than the calendar year and refer to the period 01.04.2024 - 31.03.2025.

NOTE 1: General information

General information regarding the Company:

SC Terapia SA is a Romanian company, part of the Sun Pharmaceutical Industries Limited since 25 March 2015, engaged in the manufacturing of pharmaceutical products.

The Company’s headquarters are located at 124 Fabricii Street, Cluj- Napoca, Romania.

The Company has the following branches:

- Cluj Napoca, B.dul Muncii no. 10 – business offices;
- Bucharest, Splaiul Unirii, no, 313 – manufacturing site – without operating activity;
- Pata Rat no. FN, county Cluj – residual products warehouse;
- Bucharest, B.dul Dimitrie Pompeiu no, 9 – 9A –business offices;
- Other offices in: Iasi, Brasov, Timisoara, Constanta, Craiova, Galați.

The main shareholder is Sun Pharma (Netherlands) B.V., a limited liability company, organized under Dutch laws, with headquarters at Polarisavenue 87, 2132JH HOOFFDORP, Amsterdam, Netherlands, and is registered with the Trade Registry in Amsterdam under registration number 33254757.

Sun Pharma (Netherlands) B.V. is part of Sun Pharmaceutical Industries Limited since 25 March 2015.

The first consolidation is analysed at the level of Sun Pharma (Netherlands) B.V. which owns the majority of the share capital of SC Terapia SA.

The next level of consolidation is at Sun Pharmaceutical Industries Limited (parent company) Mumbai.

NOTE 1: General information (continued)

Management structure as of 31 March 2025:

At the end of the year, the Company's Management consisted of the following individuals:

| Position | Name |
|-------------------------|---------------------------|
| General Manager | Damian Dragoș-Eugen |
| Financial Manager | Arora Hemant |
| Human Resources Manager | Kaupert Erika |
| Economic Manager | Bucur Paul Cosmin |
| Operations Manager | Chiorean Adrian Alexandru |
| Commercial Manager | Ungureanu Bogdan Alin |

Members of the Board of Directors as of 31 March 2025:

| Position | Name |
|-----------------|--------------------------|
| President | Damian Dragoș-Eugen |
| Member | Savla Prashant Lakhamshi |
| Member | Sethuraman Viswanathan |

The audit fees for 2025 amount to RON 286,638, from which RON 102,166 are due for Statutory Financial Audit.

NOTE 2: Accounting principles, policies and methods

A. ACCOUNTING PRINCIPLES

The elements included in the annual financial statements are evaluated in compliance with the following general accounting principles, according to the accrual basis of accounting. These principles are outlined below:

1. *The going concern principle* – this principle assumes that the Company will continue its normal operations, without initiating a dissolution procedure or significantly reducing its activity.
2. *The consistency principle* – this principle assumes that the Company applies consistently the same rules and standards regarding assessment, recording into accounting and presentation of assets, liabilities and results, ensuring the comparability over time of the accounting information presented.
3. *The prudence principle* – this principle that assumes that the Company in its assessment of the various accounting estimates made must follow a conservative approach and especially:
 - Only the realized profit up to the balance sheet date may be reflected in its results;
 - All known debts during the current financial year or during a preceding financial year must be taken into account, even if these become evident only between the balance sheet date and the financial statements issuance date;

NOTE 2: Accounting principles, policies and methods (continued)

- All foreseeable duties and potential losses that appeared during the current financial year or during a preceding financial year must be taken into account, even if these become evident only between the balance sheet date and the financial statements issuance date;
 - All value adjustments caused by impairment must be taken into account, irrespective of whether the result for the financial year is a loss or a profit.
4. *The accrual accounting principle.* Revenues and expenses related to the financial year are recognized, regardless of the date of collection or payment of these revenues or expenses.
 5. *The separate assessment principle of the assets and liabilities.* According to this principle, separable assets or liabilities must be assessed separately.
 6. *The intangibility principle.* The opening balance sheet for every financial year must correspond to the closing balance sheet of the previous financial year.
 7. *The non-compensation principle.* Any compensation between individual assets and liabilities or between revenues and expenses is prohibited, possible compensations between receivables and payables of the entity towards the same entity may be affected, observing the relevant provisions of the laws, only after recording in the accounting records the entire value of the related revenues and expenses.
 8. *Accounting and presentation of balance sheet and income statement items taking into account the economic substance of the transaction or of the commitment.* This requires that economic transactions to be accounted for in accordance with economic reality, putting out rights and obligations/liabilities, and risks associated with these operations.
 9. *The principle of valuation at acquisition cost or production cost.* The items in the financial statements usually are assessed at acquisition cost or production cost. The accounting regulations provide situations where this principle can not be respected.
 10. *The materiality principle.* Any element that has a significant value must be separately presented in the financial statements.

The financial statements were prepared and presented in accordance with the above-mentioned principles.

B. SIGNIFICANT ACCOUNTING POLICIES

Reference currency

The financial statements are presented in RON.

Rounding of the amounts presented was made to plus or minus 1 RON based on two decimals.

NOTE 2: Accounting principles, policies and methods (continued)

Basis of preparation

These standalone financial statements of the SC Terapia SA were prepared in accordance with the Order of the Ministry of Public Finance no. 1802/2014, modified and completed and in accordance with the Accounting Law 82/1991 (republished).

According to the requirements of OMF 1802/2014, these financial statements were prepared in accordance with the applicable requirements of the Romanian laws and regulations.

The source accounting records, on which these financial statements are based, are maintained in RON using the historic cost basis, except where specifically mentioned in the accounting policies on a fair value basis.

The Company opted for a financial year different than the calendar year, the financial year begins on April 1 and ends on March 31. The Company prepared these financial statements for 12 months ended at 31.03.2025, using the trial balance which is in compliance with the regulations outlined above.

These financial statements comprise of:

- Balance sheet;
- Profit and loss account;
- Statement of changes in equity;
- Cash flow statement;
- Explanatory notes.

Translation of amounts denominated in foreign currency

Transactions denominated in foreign currency made by the Company are registered in RON at the rate of exchange in force at the date of the transaction.

Exchange rate differences resulting from these transactions and from the translation of assets and liabilities denominated in foreign currency are presented in the profit and loss account. These balances are translated into RON at the rate of exchange in force at the balance sheet date, as published by the National Bank of Romania.

As of 31.03.2025, the exchange rates for conversion of balances expressed in foreign currency were 1 USD = 4.6005 RON, 1 EUR = 4.9771 RON, 1 GBP = 5.9460 RON, 1 CHF = 5.2179 RON, 1 PLN = 1.1892 RON și 1 RUB = 0.0538 RON.

Comparative statements

For each element of the balance sheet, profit and loss account and the related explanatory notes to the financial statements, where considered necessary, the values of the corresponding elements for the previous financial year are presented.

If the values for the prior period are not comparable with the ones of the current year, this aspect is presented and explained in the explanatory notes.

NOTE 2: Accounting principles, policies and methods (continued)

Tangible fixed assets

Tangible fixed assets are initially recorded at their acquisition cost, production cost, contribution value or fair value, as the case may be, depending of the way of entrance into the Company.

The Company recognizes as tangible fixed assets those assets which are intended for use on a continuing basis and which have an entry value established by law.

Tangible fixed assets are presented in the balance sheet at cost less accumulated depreciation and impairment, if applicable.

Revaluations are made with sufficient regularity such that the book value does not differ from the fair value at the balance sheet date.

Tangible fixed assets that are disposed in the year are eliminated from the balance sheet together with the corresponding accumulated depreciation.

Gains or losses resulting from the disposal of a tangible fixed asset are determined as the difference between the disposal proceeds and their unamortized value, including the disposal costs, and are presented in the profit and loss account under revenues or expenses, as applicable.

Subsequent expenses corresponding to a tangible fixed asset are generally recognized as an expense in the period in which they are incurred.

Significant improvements (modernizations) are capitalized if they extend the useful life of the asset, or significantly increase the estimated economic benefits to be derived from the use of these assets in the future.

Repairs and minor improvements are recognized in the profit and loss account as incurred.

Land and buildings owned by the Company are presented at fair value which is equal with the market value. The accounting of land is held on two categories: land and land improvement.

Tangible assets in progress represent investments in progress carried out under the own administration or by contract. They are valued at the production costs or the acquisition cost, as the case may be.

The tangible assets in progress are included under the category of assets completed after taking over, commissioning or putting into operation thereof, as the case may be.

Depreciation

The depreciation of tangible fixed assets is calculated using the straight-line method, starting from the month following their commissioning, so that the cost or the value of the assets may be expensed over their entire estimated useful lives.

NOTE 2: Accounting principles, policies and methods (continued)

The useful lives established for different tangible fixed assets categories are presented in the following table:

| Category | Years |
|--|--------------|
| Buildings | 10-50 |
| Technological equipment | 3-20 |
| Measurement, control, regulation devices and installations | 3-15 |
| Vehicles | 3-15 |
| Furniture, office equipment, other tangible fixed assets | 3-10 |

The depreciation period and the remaining useful lives of the tangible fixed assets are reviewed periodically in order to ensure that they are consistent with the estimated flow of the economic benefit resulting from their usage.

Land is not depreciated while land improvements are depreciated on a period of 10 years from the date of the reception.

Revaluation

Revaluation of tangible fixed assets is carried using their fair market value, as of the balance sheet date, by qualified valuation experts.

Revaluation is carried out on a regular basis, so that the accounting value of tangible fixed assets will not differ substantially from that which would be determined using their fair value as of the balance sheet date.

At the revaluation of a tangible asset, the accumulated depreciation at the revaluation date is eliminated from the asset gross book value and the net value, assessed further to the correction by the value adjustments, is recomputed at the asset revaluated value.

Intangible assets

Intangible assets are recognized when the realization of future economic benefits by the Company is probable and the asset's cost may be accurately assessed.

Intangible assets are initially recorded at their acquisition or production cost. Following initial recognition, intangible assets are presented in the balance sheet at their original cost, less accumulated amortization and impairment, if applicable.

An intangible asset reported initially as an expense will not be recognized afterwards as a part of the cost of an intangible asset.

Subsequent expenses corresponding to an intangible fixed asset and also the writing off or the demise of the intangible assets follow the rules of tangible assets.

Intangible assets comprise:

- set up costs;
- development costs;
- concessions, patents, licenses, trademarks, similar rights and assets, except for those created inside the entity;

NOTE 2: Accounting principles, policies and methods (continued)

- goodwill;
- pre-payments;
- other intangible assets.

The intangible assets of the Company include manufacturing patents (product dossiers) and software.

New software is capitalized at its acquisition cost, provided that the software component is not included with the cost of the respective hardware.

Intangible assets amortization

Intangible assets are amortized on a linear basis on the useful life time specified for each category of intangible assets. The useful life time is established for each category of intangible assets. The period and the amortization method are reviewed at the end of each financial year.

The software is amortized on a linear basis on the useful life time estimated, but no more than 3 years.

The fabrication licenses are amortized on a linear basis on a period between one and five years depending on the value of the intangible asset, starting from the date of obtaining marketing authorization, as follows:

- 1 year for licenses worth up to \$ 10,000 per product;
- 2 years for licenses worth between \$ 10,001 and \$ 20,000 per product;
- 3 years for licenses worth between 20,001\$ and 30,000\$ per product;
- 4 years for licenses worth between 30,001\$ and 50,000\$ per product;
- 5 years for licenses with values exceeding \$ 50,001 per product.

The Company holds all the intellectual property right for the “Ureactiv” brand, purchased from a third party, which is amortized over a period of 120 months according to the estimates made by the Company’s management and the accounting policy of the Company.

The set up costs are amortized over a maximum period of 5 years.

The development costs are amortized over the contract period or over the utilization period, as the case may be.

The concessions are amortized on the usage period established by the contract.

When the goodwill is treated as an asset – in the terms established by the applicable accounting regulations - we have to consider the following constraints:

- a) goodwill is amortized over a period of maximum five years;
- b) nonetheless, in exceptional cases, when the life of the goodwill can not be estimated reliably, the entity can amortize the goodwill in a systematic way over a period of up to 10 years.

Licenses and goodwill are tested for impairment at the end of each year.

NOTE 2: Accounting principles, policies and methods (continued)

Financial investments

The financial assets comprise the shares in affiliated companies, the loans granted to affiliated companies, the participating interests, the loans granted to companies with which the Company in cause is connected in virtue of participating interests, other investments held as assets, other loans.

Warranties, deposits and any security filled by the entity to third-parties are recognized in other receivables.

At balance sheet date, the Company recognizes in financial assets, the other receivables with maturity less than 12 months, the difference is recognized in receivables.

The financial assets which are recognized as assets shall be evaluated at the acquisition cost or the value assessed by the contract of acquiring thereof.

Financial assets shall be disclosed in the balance sheet at the entry value, less the cumulated adjustments for the loss in value.

CURRENT ASSETS

Acknowledgment and valuation of current assets

An asset is classified as a current asset under the following conditions:

- a) is acquired or produced for own use or for sale in the normal operating cycle of the entity;
- b) is held, mainly, for the purpose of trading;
- c) is expected to be realized in a period of 12 months from the balance sheet date;
- d) is represented by non-restricted cash or cash equivalents.

Current assets must be valued at their acquisition cost or production cost, as the case may be, and respecting the paragraph below.

The adjustments in the value of current assets are made for the purpose of their presentation at the smallest market value or, under special circumstances, at another minimum value which can be assigned at the balance sheet date.

Inventories

At the entry in the Company, the stocks are valued at cost. The cost of stocks must include all costs related to the acquisition and processing, as well as other costs incurred to bring the stocks under the current shape and at the location where they are. Below is each category of stocks with their specifics.

Raw materials and packaging materials are recorded at entry and exit at standard cost.

At the end of the reporting period, the effective cost is calculated using the weighted average cost method ("WAC") for the reporting period. At this price, the value of movements and the balance of stocks is recalculated.

NOTE 2. Accounting principles, policies and methods (continued)

Consumable materials stocks are valued at entry at effective cost. At exit, stocks are valued at effective cost using the weighted average cost method.

Trade goods are goods purchased for resale. They are valued at entry at effective cost. At exit, stocks are valued at effective cost using the weighted average cost method

The finished goods are registered during the month at standard cost. At the end of the reporting period the effective cost of production is being calculated. The differences between the standard cost and the effective cost of the finished goods are registered in differences accounts so the finished goods are registered in the balance sheet at the effective cost.

The selling or the consumptions of the finished goods is done at effective cost, using WAC method. The cost differences for the articles that exit are established as the difference between the value of the products out at standard cost and the value of the products out at effective cost.

The semi-finished goods are registered during the month at standard cost. At the end of the reporting period the effective cost of semi-finished goods is being calculated; the procedure is similar with the one for finished goods.

Work in progress refers to the unfinished production orders at the end of the month. Work in progress is registered during the month at standard cost. At the end of the reporting period the effective production cost of each stage of manufacturing of each order that compose the work in progress is calculated. At the end of the month, the work in progress is recorded at effective production cost, similar to finished goods and semi-finished goods. The cost of work in progress comprises the cost of raw material and packaging material in line with the production recipes.

The standard cost consists of indirect costs on the stock from the previous period, based on information obtained after the allocations of cost and current consumption of raw materials and packaging materials as manufacturing recipes.

The production cost of the finished goods and semi-finished goods contains:

- direct production costs (raw materials and consumables, according to the manufacturing recipes);
- indirect production costs which refer to any expenses that compete indirectly to obtain the finished goods, namely: salaries and related taxes, depreciation, maintenance and repair services, utilities, and other services provided by third parties.

Also, other assets can be presented in the inventories if they meet the requirements for recognition established by the accounting regulations.

At the balance sheet date the inventories are valued at net realizable value. For this purpose, when it is the case, in accounting are reflected the adjustments for depreciation of value.

NOTE 2: Accounting principles, policies and methods (continued)

The value of inventory write-offs is calculated as follows:

1. Expired & Near Expiry Stock

All those inventory items which are expired as on valuation date and which will expire in next 180 days will be provided at 100% of stock value.

2. Discarded or Rejected Stock

All those inventory items which are identified as discarded / rejected expired as on valuation date will be provided at 100% of stock value.

3. Non – Moving Stock

All those inventory items which are not consumed / sold during 365 days preceding the date of valuation will be identified based on Specific Identification Method and will be provided at 100% of stock value.

When the Company's management considers that there is a supplementary risk related to inventories valuation, risk which is not covered by the adjustments mentioned above, a supplementary value adjustment will be recognised.

For finished goods and goods for resale a supplementary value adjustment is recognised, if it is needed, so that these inventories are recognized at net realizable value.

As for purchased goods in foreign currency, that are accompanied by an invoice or a transfer document, for which the invoice will come afterwards, the exchange rate used for accounting registration is the one from the date of the reception of the goods.

The inventories are evidenced in synthetic accounts, on inventory categories. The analytic evidence is organized on a quantity-value base, on each article, on inventory categories and administrations.

Short term investments

Short term investments include the titles owned to affiliate entities and other short term investments (bond purchased for realizing profit on a short term shares), short term bank deposits.

On initial recognition, the short term investments are valued at the acquisition cost (purchasing cost, or the value established in contracts).

Foreign currency short term bank deposits are booked at creation at the exchange rate communicated by the National Bank of Romania at the date of creation.

The liquidation of the foreign currency short term bank deposits is made at the exchange rate communicated by the National Bank of Romania at the liquidation date.

If necessary, at the balance sheet date, adjustments for losses in value can be recorded in accounting.

NOTE 2: Accounting principles, policies and methods (continued)

Cash and cash equivalents

The bank accounts include: assets to be received such as checks and trade bills deposited with the banks, local and foreign currency liquidities, entity's check books, overdraft facilities granted in the bank current accounts and utilized at the end of the reporting period, as well as the interests related to liquid assets and bank credits in the current accounts.

The accounting of cash existing in the banks/entity's cashier desk as well as of its movement resulted from the receipts and payments made in cash, are kept separately in RON and foreign currency.

The current bank accounts are developed in the analytic on each individual bank.

The operations referring to the foreign currency amounts received and payments shall be recorded in accounting books at the rate of exchange of the day in which the operations have been performed, as communicated by the National Bank of Romania.

At the end of each month, the exchange rate differences resulting from the valuation of liquid assets in foreign currency and other treasury values, such as state bonds in foreign currency, letters of credit and short term deposits in foreign currency, communicated in the last banking day of each month by the National Bank of Romania, are recorded in the accounting books as financial revenues or expenses from currency exchange differences, as applicable.

Third parties' receivables and debts

The accounting system of third parties ensures the records of the receivables and debts of the entity in its relation with the suppliers, customers, personnel, state authorities, affiliated companies, shareholders/partners and various other debtors and creditors.

The operations regarding purchases or deliveries of commodities and products, works performed or services supplied, as well as other operations performed are recorded in the accounting books of suppliers and customers.

The accounting of settlements with the personnel comprises salary rights, raises, additional amounts, prizes from salary fund, indemnities for holidays as well as those for temporary work incapacity and other rights in cash and/or in kind owed by the entity to the personnel in consideration for the work supplied and which is to be borne, according to regulations in force, from the salary fund.

The accounting of settlements regarding social contributions comprises liabilities for the social security contribution, health insurance contribution and unemployment contribution.

The settlements with the state budget and special funds comprise: tax on profit/income, value added tax, income tax, subsidies to be received and other similar taxes, fees and payments.

The profit/income tax payable must be recognized as a debt within the unpaid amount. If the amount paid exceeds the amount due, then the surplus must be recognized as debenture.

NOTE 2: Accounting principles, policies and methods (continued)

The Company computes profit tax for individual financial statements prepared in accordance with the law in force, and in compliance with tax legislation in force.

The value added tax owed to the state budget shall be determined as the balance between the value of the chargeable tax related to the goods delivered or services performed (input VAT) and the value of the deductible tax for purchases of goods and services (output VAT).

Other taxes, fees, and payments owed to the state budget or to local budgets comprise: tax on buildings, tax on lands, dividends tax, tax on transportation means and other taxes and fees. These taxes are separated in the analytical accounting by types of taxes, fees and other payments owed to the state budget or to local budgets.

The excise duties and special funds included in prices or tariffs are recorded in the appropriate debts accounts without passing through income and expenses accounts.

The accounting of settlements within the group companies and with the shareholders/partners includes the operations that are reciprocally recorded in the books during the same administration period both in the debtor entity's accounting and in that of the creditor entity, as well as the settlements between the shareholders/partners and the entity in respect of the share capital, the dividends owed there to, other settlements with the shareholders/partners, and also the participants' accounts in respect of the joint transactions in the case of the partnership associations.

Dividends distributed to shareholders, proposed or stated after the balance sheet date, as well as other similar distributions performed from the profit, need not be recognized as a liability at the balance sheet date.

The entity's debts/debentures to other third parties, other than own personnel, customers and suppliers are recorded in the books under the various debtors' accounts.

Taxes payable are recorded for the period for which they are due.

During the annual inventory, for the depreciation of the receivable balances (customers, sundry debtors, related parties), the Company records adjustments.

The policy for receivables value adjustments is presented below:

- For customers in litigation will be recorded a provision of 100%, at the level of outstanding balance;
- For receivables older than 365 days from the invoice date will be recorded a provision of 100%;
- For domestic customers, others than those mentioned above in paragraphs 1 and 2 there will be recorded a provision based on risk analysis that the Company is exposed by dividing the Company litigations occurred in the last financial years to the average customer balance for the same financial years.

The percentage result applying the litigations to the average customer balance is applied to year end domestic customer balance resulting the provision corresponding to the current financial year.

During the year, it will follow the same procedure keeping the percentage results from dividing the litigations to year end average customer balance applied to respective month customer balance.

NOTE 2: Accounting principles, policies and methods (continued)

If there are signs that this percentage will not reflect market conditions, this percentage will be reanalysed.

- Specific provision in relation to the customer balances for which, at the balance sheet date, there are objective indications that will become insolvent or bankrupt.

In order to compute the provision/adjustment according to the information presented above, the promissory notes are not considered.

If a company within the group presents documents attesting the transfer of money which represents the value of a receivable, the Company will present in its records the amounts under settlement and will settle the receivable.

The receivables and payables in foreign currency, as a result of the transactions incurred by the Company are recorded in accounting both in RON and in foreign currency. A foreign currency transaction has to be initially recorded at the exchange rate communicated by the National Bank of Romania from the date of the transaction.

The foreign currency exchange differences as compared to the date of the settlement of receivables and debts in foreign currencies at rates of exchange different from those initially recorded in books during the month or as compared to those at which they were disclosed in the previous month must be recognized as revenues or expenses during the period when they are derived or incurred.

When the receivables or debts in foreign currency are settled during the same month as that when they occurred, the entire foreign exchange difference shall be recognized in that month. When the receivable or the debt in foreign currency is settled during a later month, the foreign exchange difference which occurs until the settlement shall be assessed taking into account the change of the exchange rate occurred during each of such month.

At the end of each month, the receivables and debts in foreign currency are revalued at the exchange rate communicated by the National Bank of Romania from the last banking day of that month. The exchange rate differences encountered are recorded as exchange rate revenues or expenses, as the case may be.

The above provisions are applicable to the receivables and debts in local currency whose settlement is made according to the exchange rate of a foreign currency. In this case, the exchange rate differences incurred are recognized in accounting under other financial revenues or other financial expenses, as the case may be.

The accounting books of third parties are kept by categories, in distinct accounts and the analytical accounts for each individual or legal person, grouped by documents and due dates.

Accounting of commitments and of other off-balance items

The rights and liabilities, as well as certain goods that cannot be included in the entity's assets and liabilities are recorded in books under accounts off balance sheet called order accounts and record accounts.

NOTE 2: Accounting principles, policies and methods (continued)

This category includes commitments (endorsements, bails, guarantees) granted or received in relation to third parties, tangible assets taken on hire, material values received for processing or repair in keep or custody, debtors removed from assets and further pursued, royalties, administrations, rental fees and other similar debts, discounted trade bills not due yet, as well as other securities.

A distinct category of off balance items are the contingent assets and debts.

A contingent asset is a probable asset which appears as a result of events before the balance sheet date and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the entity.

A contingent liability is:

- a) a possible liability as a result of past events occurred before the balance sheet date and whose existence will be confirmed only by the occurrence or non- occurrence of one or more uncertain future events not wholly within the control of the entity, or
- b) a present obligation as a result of past events occurred before the balance sheet date but which is not recognized because:
 - it is not probable that an outflow of resources embodying economic benefits will be required to settle the obligation; or
 - the amount of obligation cannot be measured with sufficient reliability.

The contingent assets and liabilities are not shown in the balance sheet, Information is disclosed in the notes to the financial statements.

Short term debts: amounts which must be paid during a period up to one year

A debt must be classified as a short term debt, also referred to as current debt, when:

- a) it is expected to be settled during the normal operating cycle of the entity;
- b) it is chargeable within 12 months as of the balance sheet date.

Long term debts: amounts which must be paid during a period exceeding one year

The accounting of loans and debts similar to loans is kept under the following categories: loans from bonds and repayment premiums thereof, long and short term bank loans, amounts due to affiliated companies and to those to which participating interests are held, other similar loans and debts, as well as interest related thereof.

Provisions

A provision is a liability of uncertain exigibility or value.

A provision is recognized when the Company has a current (legal or constructive) obligation resulting from a past event, when it is likely that an outflow of resources carrying economic benefits may result from the settlement of these obligations, and when the value of the payment can be measured reliably.

NOTE 2: Accounting principles, policies and methods (continued)

Provisions are reviewed at the end of each year and adjusted in order to reflect an accurate estimation of the losses that might occur, estimation made taking into consideration all the information known at the moment when the financial statements are prepared.

Provisions are set for items such as:

- a) litigations, fines or penalties, damages, compensations and other uncertain debts;
- b) expenses in connection to the service activity during the guarantee period and other expenses regarding the guarantee granted to the customers;
- c) tangible assets decommissioning and other similar actions related to it;
- d) restructuring activities;
- e) retirement pensions and other similar liabilities;
- f) taxes;
- g) completion of the employment contract;
- h) premiums to be granted to staff depending on the profits made, according to legal or contractual provisions;
- i) provisions related to concession agreements;
- j) provisions for pecuniary interest contracts;
- k) other provisions.

The accounting of provisions is kept depending on the types of provisions, according to their nature, purpose and the scope for which they were established.

The Company sets provisions for litigations, completion of the employment contract, environment expenses and for other taxes.

The Company records the provisions for taxes in relation to amounts representing future fiscal consequences of items that currently generate taxable temporary differences between their accounting base and tax base.

When the provision is no longer necessary for the purpose for which it was established, it is reversed as income.

Subsidies

Subsidies comprise subsidies related to assets and subsidies related to revenues.

The following shall be disclosed separately under subsidies:

- government subsidies;
- non-reimbursable loans like subsidies;
- other amounts received as subsidies.

Subsidies related to assets have the effect of purchase / acquisition / construction of fixed assets.

Subsidies related to income comprise all the subsidies other than those for assets.

A government subsidy may take the form of the transfer of a non-monetary asset, and in this case the subsidy and the asset shall be recorded in books at the fair value.

NOTE 2: Accounting principles, policies and methods (continued)

Inventory excess of tangible and intangible assets and the donations are also recorded in accounting under the subsidy accounts.

The subsidies shall be systematically recognized as revenues of the periods corresponding to related expenses which these subsidies are to off-set.

The accounting of subsidies is kept under applicable accounting regulations and considering contractual provisions when appropriate.

The subsidies are not recorded in books directly under the capital and reserves accounts.

Equity

Equity represents the residual interest of shareholders in the entity's assets after deducting all liabilities.

The subscribed and paid in share capital is separately recorded in the accounting books, based on the incorporation articles of the legal person and the justifying documents as regards the capital payments.

Share premiums (issuance, merger, contribution, conversion) are the excess of the issuance value less the par value of the shares or social parts.

The accounting of reserves is kept by reserve categories as follows: legal reserves, statutory reserves or contractual reserves and other reserves.

In accordance with the Romanian legislation, companies must allocate an amount equal to at least 5% of the profit before taxation to legal reserves, until the value of the legal reserves reaches 20% of the value of capital. Once the legal reserves reach this level, the Company may allocate additional funds to the legal reserves, depending on its own requirements.

Statutory or contractual reserves are formed on annual basis from the entity's net profit, according to the provisions in its incorporation articles.

Other reserves not provided for by law or by statute may be formed optionally, based on the net profit, to cover the accounting losses or for other purposes, according to the decision of the general shareholders or partners meeting, by observing the legal provisions.

Revaluation reserves

Pluses or minuses resulted from the revaluation of non-current assets are recognized in revaluation reserve.

The revaluation reserves decrease can be made only in the limit of the existing credit balance.

The revaluation reserve must be reduced to the extent that the amounts transferred there to be no longer necessary for the implementation of the valuation method used.

The revaluation reserves of non-current assets have a non-distributable character.

NOTE 2: Accounting principles, policies and methods (continued)

The revaluation surplus included in revaluation reserve is capitalized through direct transfer in retained earnings, as long as the surplus is achieved.

The gain is considered realized as long as it is used by the entity and depreciated.

Transfer between reserves is realized on a quarterly basis and at the end of the financial year.

The value of the transferred reserve is equal with the difference between depreciation of the asset computed at the gross revaluated value and the depreciation computed at the initial cost of the asset.

Profit and loss

Profit and loss is established on a cumulative basis from the beginning of the financial period, as the difference between income and expenditure of the period. The final result of the financial period is established at the end of the exercise and represents the final balance of the profit and loss account.

The distribution of the profit is registered in accounting based on destination after the approval of the financial statements.

The profit distribution is made in accordance with the decision of general meeting of the shareholders according to the Romanian law.

The amounts representing reserves created from the profit of the current financial year are shown under the account "Profit appropriation", according to legal provisions.

The profit which is not distributed is transferred to retained earnings.

The retained result from changes in accounting policies and the retained result from correction of accounting errors are separately highlighted in the retained earnings.

The accounting loss reported is covered from the profit of the financial exercise and the reported one, from reserves, and equity, in accordance with the general meeting of the shareholders, according to the Romanian law.

Revenues

Revenues are increases of economic benefits registered during an accounting period as inputs or increases of assets or decreases of liabilities, which materializes as a growth of shared capital, other than the shareholders contribution.

Revenues are recognized in the profit and loss account when it is likely that the Company will derive the benefits associated with the underlying transactions, and a reliable estimate of the value of these benefits can be made.

The accounting of revenues is kept depending on the types of revenues, according to their nature, as follows:

- a) operating revenues;
- b) financial revenues.

NOTE 2: Accounting principles, policies and methods (continued)

Operating revenue comprise:

- a) revenues from the sale of products and commodities, work performed and services supplied;
- b) revenues from inventory variation;
- c) revenues from the production of assets;
- d) revenues from operating subsidies;
- e) other revenues from the current activity.

Revenues from the sale of goods are recorded in accounting books at the moment of handing over the goods to the purchaser, of the delivery of the goods based on invoice or in other conditions as provided for in the contract, which certify the transfer of the ownership right on such goods, to the customers.

Revenues from the sale of goods are recognized at the moment when the following conditions are met:

- a) the entity has transferred the material risks and benefits deriving from the ownership of goods to the purchaser;
- b) the entity does not administrate the sold goods and does not have control over them;
- c) revenues and expenses respectively derived or incurred by the transaction may be quantified,
- d) it is probable that the economic benefits will be generated for the entity and;
- e) the costs of the transaction can be valued in a credible manner.

The other categories of revenue are recognized if they meet the requirements for recognition established by the accounting regulations.

Financial revenues comprise:

- a) revenues from financial assets;
- b) revenues from short term investments;
- c) revenues from financial investments ceded;
- d) revenues from foreign exchange differences;
- e) revenues from interest;
- f) revenues from discounts received further to financial reductions;
- g) other financial revenues.

The financial discounts are given for a non-commercial scope, usually for stimulating the customer to pay early or to stimulate him to use a certain payment form, it is not committed to a certain product but to a payment value and to a payment frequency.

The financial discounts received are registered as financial revenues for the period.

Expenses

Expenses are reductions of economic benefits registered during an accounting period as outputs or reduction of value of assets or increases of liabilities, which materializes as a reduction of shared capital, other than the shareholders withdrawals.

The accounting of expenses is kept on types of expenses, according to their nature, as follows:

- a) operating expenses;
- b) financial expenses.

NOTE 2: Accounting principles, policies and methods (continued)

Operating expenses includes:

- a) expenses for raw materials and consumables; the acquisition cost of consumed inventory objects; acquisition costs of not inventorized materials, directly recorded as expenses; the equivalent of the energy and water consumed; the value of biological assets such as inventories; the cost of goods sold and of packages;
- b) expenses for works and services supplied by third parties, royalties and rental; insurance premiums; studies and research; expenses for other services performed by third parties (collaborators); commissions and fees; protocol, advertising and publicity expenses; transport of goods and personnel; travels, official trips and transfers; postage expenses and telecommunication duties, banking services and others;
- c) personnel expenses (salaries, social security, meal tickets and other personnel expenses which are borne by the entity);
- d) other operating expenses (expenses related to environmental protection, losses from debentures and various debtors; compensations, fines and penalties; donations and other similar expenses; expenses regarding ceded assets and other capital expenses etc.),

Financial expenses, which comprise:

- a) losses from debentures in connection to participations;
- b) expenses regarding financial expenses;
- c) unfavourable foreign currency differences;
- d) interest regarding the current financial year;
- e) discounts granted to customers;
- f) losses for debentures of financial nature and others.

Financial discounts granted to customers are booked in accounting as financial expenses of the period.

Turnover

The profit and loss account comprises: the net turnover, incomes and expenses of the financial year grouped by their nature, as well as the result of the period (profit or loss).

For purposes of these regulations, the net turnover is computed by summing up the income resulted from deliveries of goods, performance of services and other operating income, less trade rebates granted to the customers and value added tax and other taxes related directly to the turnover.

Trade rebates are granted to customers for specific product during a specific period of time and have the purpose to increase the sales of that product for that period of time. This kind of trade rebates will generate a reduction of trade income and also of net turnover.

Retirement, post retirement and termination benefits

- Short-term employee benefits

Short-term employee benefits comprise salaries and contributions to social security funds. They are recognized as expenses in the period in which they are paid.

NOTE 2: Accounting principles, policies and methods (continued)

Both the Company and the employees have the obligation to contribute to the National Retirement Fund. The Company has no obligation of paying other future benefits. The only obligation in this respect is the payment of the contributions to the National Retirement Fund by the due date.

- Retirement benefits

Upon retirement the employees receive a bonus equal with two gross average salary in compliance with the provisions of the collective labour agreement. The Company has recorded provisions for these obligations.

- Benefits upon terminating of individual labour agreements

The Company has an obligation to compensate employees in case it terminates their individual labour agreements, as a result of making the respective employees redundant. The magnitude of the related termination benefits payable depends on the position held and the number of years of employment with the Company. Termination benefits obligations are recorded when the related reorganization plan is adopted by the management of the Company or when the expenses are made if there is no reorganization plan in force, according to the collective labour agreement.

Leasing contracts

The leasing contract is an agreement through which the lessor gives to the lessee, in exchange of a payment or a serial of payments, the right to use a good for a period of time.

Financial leasing

The financial leasing is the leasing operation which transfers the most important part of the risks and advantages of a property right over an asset.

A leasing contract can be known as a financial leasing if it fulfils at least one of the following conditions:

- a) the lessor transfers to the lessee the property right over the asset until the leasing contract is finished;
- b) the lessee has the option to buy the asset at a price estimated to be small enough comparing to the market value at the date when the option becomes realizable, so that, at the beginning of the leasing contract there exists in a reasonable way the certitude that the option will be realized;
- c) the leasing contract duration covers for the most part the economic life time of the asset, even if the property right is not transferred;
- d) the total value of the leasing rates, less the accessories costs, is greater or equal to the acquisition value of the asset, represented by price paid by the lessor for the asset, respectively the acquisition price;
- e) the asset that represent the object of the leasing contract has a special nature, so that only the lessee can utilize them without any major modifications.

The leasing payments are separated between the interest and the reduction of the leasing debt to obtain a constant interest rate that applies to the final balance of the debt. The interest expense is booked directly into the profit and loss.

NOTE 2: Accounting principles, policies and methods (continued)

The acquisition of assets in the case of financial leasing is treated as investment, being depreciated on a consequent base with the normal depreciation policy used for similar assets.

Operational leasing

The operational leasing is the leasing operation that is not included in the financial leasing category.

The payments for an operational leasing contract are recognized as expenses in the profit and loss account, linear during the leasing contract.

Leaseback

A selling transaction of a long term asset and a rental transaction of the same asset in leasing (leaseback) are registered as follows (taking into account the leasing contract):

- a) if the transaction of selling and renting the same asset has as a result a financial leasing, the transaction represents a way through which the lessor gives to the lessee a financing, in this case the asset is considered a guarantee. The financing beneficiary (lessor) will not insert in accounting the selling operation of the fixed asset, because the conditions to recognize income are not met. The fixed asset will remain recorded at the value before the leasing operation, with the corresponding depreciation regime;
- b) if the sell and lease operation of the same fixed asset has as result an operational leasing, the selling party accounts a selling transaction, including the recording of the fixed asset as being taken out of accounting, along with all the amounts that have been cashed or have to be cashed.

Related parties

Parties are considered to be related if one of the parties has the ability to control, partially control or to exercise significant influence over the other party due to the following aspects:

- a) owns the majority of the voting rights of the shareholders or associates in other entity, named subsidiary;
- b) it is a shareholder or associate of an entity and the majority of the members of the administration, management and supervising authorities of the entity (subsidiary) which have been named in these functions during the financial year, during the previous financial year and by the time the annual consolidated financial statements were prepared were named only as a result of exercising its voting rights;
- c) it is a shareholder or associate of a subsidiary and owns by itself the control over the majority of voting rights of the shareholders or associates of that subsidiary, as a result of an agreement concluded with other shareholders or associates;
- d) it is a shareholder or associate of a subsidiary and has the right to exercise a dominant influence over that subsidiary, based on a contract concluded with the entity or on a clause in the constitutive deed or statute, if the regulation applicable to the subsidiary allows such contracts or clauses;
- e) Parent Company has the power to exercise or effectively exercises a significant influence or control over a subsidiary;
- f) it is a shareholder or associate of a subsidiary and has the right to appoint or revoke the majority of the members of the administration, management and supervising bodies of that subsidiary;
- g) parent company and the subsidiary are managed on a unified basis by the parent company.

NOTE 2: Accounting principles, policies and methods (continued)

The subsidiary represents an entity under the control of other entity, named Parent Company.

A transaction with related parties is a transfer of resources, services or obligations between related parties without being of importance if a price is charged.

Borrowing costs

Borrowing costs that are directly attributable to the assets with long manufacturing cycle are included in the production costs as far as they are related to the production period.

Borrowing costs include the interest on capital borrowed to finance the acquisition, the construction or the production of assets with long manufacture cycle.

Events occurring after the balance sheet date

The events subsequent to the balance sheet date are those events, either favourable or unfavourable, which take place between the balance sheet date and the date on which the statements on the annual accounts are to be approved under the law.

The events which occur after the balance sheet date may supply additional information. If the additional information leads to the need to record certain incomes or expenses in books, then such records must be made, in order to give a true and fair view. This information shall also be disclosed in the notes on accounts.

Correction of accounting errors

The accounting errors may relate either to current period or to previous periods.

Previous period errors are omissions and misstatements in the financial statements.

Correction of errors is made at the date of their acknowledgement.

Correction of the errors of the current period is made in the profit and loss account.

Correction of the significant errors of the previous period is made in retained earnings.

Not significant errors related to previous periods are also corrected in retained earnings. Still, they can be corrected in the profit and loss account if the errors are immaterial.

Immaterial errors are those that do not influence the information presented in the financial statements. It is considered that an error is material if it influences the economic decisions taken by the users of the financial statements. The analysis of the nature of an error is made considering the individual or cumulated value of the elements.

In case of correcting the errors which generate a carried forward accounting loss, such loss must be covered before performing any profit distribution.

The correction of errors from previous financial statements must not lead to changes in those financial statements.

NOTE 2: Accounting principles, policies and methods (continued)

In case of correcting errors from previous financial statements, these corrections must not adjust the comparative information presented in the financial statements.

Estimates

Because of the uncertainties inherent in carrying out the activities, some elements of the annual financial statements can not be measured with precision but just estimated.

The estimation process involves judgment based on the latest credible information at their disposal.

S.C. TERAPIA S.A.
NOTES TO THE FINANCIAL STATEMENTS
For the year ended 31 March 2025
(all amounts are expressed in RON, unless specified otherwise)

NOTE 3: Non-current assets

| Asset elements | | Gross book value | | | |
|----------------|---|-----------------------|---|--|-----------------------|
| | | Balance at 01.04.2024 | Increases, including the increases due to revaluation | Disposals, transfers and other discounts | Balance of 31.03.2025 |
| | 0 | 1 | 2 | 3 | 4 |
| I, | Intangible assets | | | | |
| | Licenses, trademarks and other intangibles | 360,856,921 | 528,000,413 | | 888,857,334 |
| | Other intangible assets | 6,254,978 | | | 6,254,978 |
| | Total intangible assets | 367,111,899 | 528,000,413 | | 895,112,312 |
| II, | Tangible fixed assets | | | | |
| | Land and land improvements | 153,239,892 | | | 153,239,892 |
| | Buildings | 36,634,588 | 20,677,675 | | 57,312,263 |
| | Machinery and equipment | 26,893,178 | 10,346,668 | 14,577 | 37,225,269 |
| | Other tangible fixed assets | 2,852,060 | 1,083,701 | | 3,935,761 |
| | Tangible fixed assets in progress | 21,162,860 | 17,206,229 | 32,108,043 | 6,261,046 |
| | Advances for the acquisition of tangible assets | 1,462,872 | 8,134,582 | | 9,597,454 |
| | Total fixed tangible fixed assets | 242,245,450 | 57,448,855 | 32,122,620 | 267,571,685 |
| III, | Financial non-current assets | 72,560 | 3 | | 72,563 |
| | TOTAL – Non-current assets | 609,429,909 | 585,449,271 | 32,122,620 | 1,162,756,560 |

| Asset elements | | Value adjustments (depreciation, amortization and adjustments for loss of value) | | | |
|----------------|--|--|-----------------------------|------------------------|-----------------------|
| | | Balance at 01.04.2024 | Adjustments during the year | Decreases or disposals | Balance at 31.03.2025 |
| | 0 | 1 | 2 | 3 | 4 |
| I, | Intangible assets | | | | |
| | Licenses, trademarks and other intangibles | 257,387,676 | 12,279,744 | | 269,667,420 |
| | Other intangible assets | 5,461,693 | 328,030 | | 5,789,723 |
| | Total intangible assets | 262,849,369 | 12,607,774 | | 275,457,143 |
| II, | Tangible fixed assets | | | | |
| | Land and improvements on land | | | | |
| | Buildings | | 4,817,564 | | 4,817,564 |
| | Machinery and equipment | 1,609,022 | 7,700,078 | 2,926 | 9,306,174 |
| | Other tangible fixed assets | 14,410 | 471,935 | | 486,345 |
| | Tangible fixed assets in progress | | 8,900 | | 8,900 |
| | Total Tangible fixed assets | 1,623,432 | 12,998,477 | 2,926 | 14,618,983 |
| III, | Financial non-current assets | | | | |
| | TOTAL Non-current assets | 264,472,801 | 25,606,251 | 2,926 | 290,076,126 |

NOTE 3: Non-current assets (continued)

The net book value of the non-current assets as of 31 March 2025 represents the fair value, in accordance with the provisions of the Order of the Minister of Public Finance no. 1802/20149, for approving the accounting regulations regarding the individual and consolidated annual financial statements, and the Order of the Minister of Public Finance 2861/2009 for the approval of the Regulations regarding the organization and performance of the inventory of assets, liabilities and equity.

The last revaluation was performed at 31.03.2024 by an independent valuer.

The movements in value adjustments for fixed assets for period 01.04.2024-31.03.2025, are presented below.

| Crt. No. | Name of the value adjustments | Balance at | Movements during the year | | Balance at |
|--------------|--------------------------------------|------------------|---------------------------|------------|------------------|
| | | 01.04.2024 | Increase | Reversal | 31.03.2025 |
| 0 | 1 | 2 | 3 | 4 | 5=2+3-4 |
| 1 | Impairment for tangible fixed assets | 1,623,432 | 78,583 | 206 | 1,701,809 |
| TOTAL | | 1,623,432 | 78,583 | 206 | 1,701,809 |

The value of intangible assets as of 31.03.2025 contains a newly acquired intangible asset, namely the sales license for the Fibromun product, purchased during this financial year from the company PHILOGEN S.p.A., from Italy, in the amount of RON 527,413,600. The intangible asset is disclosed under the licenses and trademarks caption both in the non-current assets table and in the balance sheet account. The Fibromun product is under trials for the treatment of advanced soft tissue sarcoma and glioblastoma.

The tangible assets category comprises land in surface of 177,147 sqm with a net book value as of 31 March 2025 of RON 153,239,892.

Furthermore, the assets owned by the Company as at 31 March 2025 comprise assets which are not currently used due to the ceasing of production activity at Bucharest site. These assets have been valued at 31 March 2025 at a net book value of RON 1,434,749.

Financial assets, amounting to RON 72,563 comprise mainly guarantees granted to Ministry of the Environment for closing and following-up after closing the residual products warehouses and a bank guarantee for the Regional Customs Directorate of Cluj for free circulation release based on a customs declaration submitted in accordance with Article 182 of Regulation (EU) no. 952/2013 of the European Parliament and of the Council of 9 October 2013 establishing the Customs Code of the Union.

The last revision of useful economic lives of tangible and intangible fixed assets was made at 31 March 2025, during the annual inventory of fixed assets.

As of 31.03.2025, the Company has assets in use that are fully depreciated. The main component in this amount is referring to plant and machinery.

The gross book value of the fully depreciated tangible fixed assets which are still in use as of 31 March 2025 is RON 167,789,859.

NOTE 3: Non-current assets (continued)

The split on categories of fully depreciated tangible fixed assets still in use is presented below:

| | |
|--|--------------------|
| Buildings | 1,500,944 |
| Technological equipment | 138,380,302 |
| Measurement, control, regulation devices and installations | 16,950,150 |
| Vehicles | 2,870,373 |
| Others | 8,088,090 |
| TOTAL | 167,789,859 |

NOTE 4: Capital investments

During the year the investments in tangible and intangible assets amounted to RON 553,329,577. The main component in this amount is represented by equipment for equipping the finished products warehouse.

Investments performed during the reporting period of 2024-2025 are for the main activities of the Company as follows:

| | |
|---------------------------------------|---------|
| • Product licenses | 95.42 % |
| • Production machinery and equipment | 2.74 % |
| • Constructions | 1.64 % |
| • Quality assurance and control | 0.14 % |
| • Information technology and software | 0.04 % |
| • Others | 0.02 % |

NOTE 5: Inventories

Inventories have a structure specific to the Company's activity, as can be seen below.

They have decreased compared to the beginning of the financial year mainly due to the reduction in the inventory of trade goods.

The evolution of inventories is controlled by management, their level as of 31.03.2025 being correlated with the requirements of the production and sales activity that will take place in April - May 2025.

On 31 March 2025, the Company owned goods and finished products, in amount of RON 2,578,991 stored in logistics facilities in Lithuania.

The structure of inventory as of 31.03.2025 is presented below:

| Stock description | 31 March 2024 | 31 March 2025 |
|--|----------------------|----------------------|
| Raw materials and consumables | 31,134,508 | 30,477,769 |
| Work in progress | 4,420,429 | 2,567,457 |
| Finished products | 22,580,206 | 26,520,787 |
| Goods purchased for resale | 108,615,499 | 95,452,326 |
| Advance payment for the purchases of inventories | 1,077,697 | 5,627,397 |
| Provisions against the carrying value of inventories | (12,343,447) | (25,133,635) |
| Total inventories | 155,484,892 | 135,512,101 |

NOTE 6: Receivables and payables

| Receivables | Balance at 31 March 2024 | Balance at 31 March 2025 | Maturity term | |
|--|--------------------------------|--------------------------------|--------------------|-------------|
| | | | Under 1 year | Over 1 year |
| 1. Trade receivables | 487,428,526 | 581,675,725 | 581,364,451 | 311,274 |
| 2. Receivables from affiliated companies | 73,243,510 | 33,964,080 | 33,964,080 | |
| 3. Other receivables | 18,456,398 | 19,505,576 | 19,505,576 | |
| 4. Provisions for receivables | (282,160) | (311,274) | | (311,274) |
| TOTAL | 578,846,274 | 634,834,107 | 634,834,107 | |

Trade receivables relate mainly to the sale of finished goods and of goods for resale.

The liquidity term is established considering the due date of the invoices as it is established in the contracts concluded with our partners. These terms do not overlap with the ageing intervals used in computation of value adjustments for receivables.

The Company's main customers are:

- DR. Max SRL
- Alliance Healthcare Romania S.R.L
- Fildas Trading SRL Pitesti
- Centrala Farmaceutyczna CEFARM S.A.
- Dona. Logistica S.A. Chitila
- Farmexim S.A. Bucuresti
- AO "Ranbaxy" Russia
- Europharm Holding SA Brasov
- Ropharma Logistic S.A.
- LLC Ranbaxy Pharmaceuticals Ukraine

| Payables | Balance at 31 March 2024 | Balance at 31 March 2025 | Repayment term | | |
|--|--------------------------------|--------------------------------|--------------------|----------------|-----------------|
| | | | Under 1 year | 1 – 5 years | Over 5 years |
| 1. Suppliers - other | 99,167,862 | 288,577,794 | 288,577,794 | | |
| 2. Suppliers - intercompany | 75,149,849 | 32,556,772 | 32,556,772 | | |
| 3. Fixed assets suppliers | 7,472,358 | 116,792 | 116,792 | | |
| 4. Advances received from customers | 45,005 | 75,687 | 75,687 | | |
| 5. Payables to employees | 23,776,393 | 9,850,372 | 9,850,372 | | |
| 6. Social security and unemployment fund | 4,086,875 | 4,422,162 | 4,422,162 | | |
| 7. Taxes and duties payable | 26,739,810 | 39,683,593 | 39,683,593 | | |
| 8. Dividends payable | 30,683,848 | 34,534,991 | 34,534,991 | | |
| 9. Other liabilities | 494,473 | 16,284,237 | 16,284,237 | | |
| TOTAL | 267,616,473 | 426,102,400 | 426,102,400 | | |

As of 31 March 2025, the suppliers' liabilities comprise the liabilities for the services and fixed assets supplied and purchased amounting to RON 202,940,951 for which the Company did not receive invoices until 31 March 2025.

NOTE 7: Cash and cash equivalents

| Description | 31 March 2024 | 31 March 2025 |
|--|-------------------|-------------------|
| Petty cash and other values | 8,693 | 2,593 |
| Cash at bank | 12,712,836 | 24,316,184 |
| Guarantees received from warehouse keepers | 313,349 | 336,796 |
| Total cash and cash equivalents | 13,034,878 | 24,655,573 |

The Company has as of 31 March 2025 restricted cash balances amounting to RON 336,796 representing guarantees received from warehouse keepers.

As of 31 March 2025 the short-term financial investments are investments in bonds in amount of RON 11,424,719.

NOTE 8: Allowances and provisions against the value of assets

Allowances and provisions were made in relation to the impairment of assets, risks and potential losses resulting from the Company's operational activities, in accordance with the prudence principle.

Provisions for receivables and inventories

For customers and inventories, the Company recorded allowances and impairment provisions according to the accounting policies presented in Note 2.

In respect of inventories, besides the provisions recorded according to the accounting policy, the Company has presented in the financial statements supplementary allowances amounting to RON 4,422,267 for goods for resale. Management considers that there is an increased risk for these goods of not being sold.

The movement during the period 01.04.2024-31.03.2025 in the value of provisions is presented in the following table:

| Crt. No. | Name of the value adjustments | Balance at 31 March 2024 | Movements during the year | | Balance at 31 March 2025 |
|--------------|---|--------------------------------|---------------------------|-------------------|--------------------------------|
| | | | Increase | Reversal | |
| 0 | 1 | 2 | 3 | 4 | 5=2+3-4 |
| 1 | Allowances for inventories | 12,343,447 | 22,893,872 | 10,103,684 | 25,133,635 |
| 2 | Allowances for doubtful trade receivables' balances | 282,160 | 32,832 | 3,718 | 311,274 |
| TOTAL | | 12,625,607 | 22,926,704 | 10,107,402 | 25.444.909 |

NOTE 9: Related parties

Transactions and balances with related parties

Transactions with related parties are carried out on an arm's length basis.

The value of the transactions that the Company entered into during 1 April 2024 – 31 March 2025 with the group companies, as well as the related balances as of 31 March 2025 are presented below.

Transactions

| Purchases of goods and services | Purchase type | 31.03.2024 | 31.03.2025 |
|--|----------------------|--------------------|--------------------|
| Ranbaxy Poland Sp Zoo | services | 43,471,604 | 47,122,526 |
| Sun Pharmaceutical Industries Ltd-SPII | goods | 212,171,743 | 236,713,498 |
| Sun Pharma (Netherlands) B.V. | services-insurance | 825,150 | 862,210 |
| Sun Pharmaceutical Ltd. Europe (SPIE) | services | 3,543,618 | 4,734,390 |
| Alkaloida Chemical Company Zrt. | goods | 324,334 | |
| Sun Farmaceutica do Brasil Ltda | goods | | 44,783 |
| Taro pharmaceutical Canada inc | goods | 1,664 | 204,155 |
| Total | | 260,338,113 | 289,681,562 |

| Sales of goods and services | Sales type | 31.03.2024 | 31.03.2025 |
|---|-------------------|--------------------|-------------------|
| AO Ranbaxy Rusia | goods | 69,993,841 | (503,500) |
| Ranbaxy UK Limited | goods | 784,361 | 1,049,454 |
| Ranbaxy Pharmacie Generique France | goods | 1,927,529 | 2,507,473 |
| | services | | 99,620 |
| Ranbaxy Poland | goods | 48,889 | 41,526 |
| Ranbaxy Italia Spa | goods | 950,577 | 1,264,438 |
| Sun Pharma Laboratorios S.L.U | goods | 113,743 | 241,247 |
| LLC Ranbaxy Pharmaceuticals Ukraine | goods | 20,680,616 | 23,784,511 |
| Sun Pharmaceutical Industries Europe BV | goods | 160,704 | 133,158 |
| | services | 12,967,562 | 14,983,546 |
| Sun Pharmaceutical Industries Ltd | goods | 8,035,904 | 34,185,716 |
| | services | 13,619,722 | 15,162,781 |
| | recharges | 840,876 | 1,756,892 |
| Sun Pharmaceuticals Germany Gmbh | goods | 1,008,858 | 1,685,422 |
| Sun Pharma Advanced Research Company | services | 580,408 | |
| Total | | 131,713,590 | 96,392,284 |

Balances

| Payables | 31.03.2024 | 31.03.2025 |
|---|-------------------|-------------------|
| Ranbaxy Poland Sp Zoo | 20,009,792 | 21,069,664 |
| Sun Pharmaceutical Industries Ltd. | 54,711,961 | 10,346,012 |
| Sun Pharmaceutical Industries Europe (SPIE) | 428,096 | 1,095,643 |
| Sun Farmaceutica do Brasil Ltda | | 45,453 |
| Total | 75,149,849 | 32,556,772 |

S.C. TERAPIA S.A.
NOTES TO THE FINANCIAL STATEMENTS
For the year ended 31 March 2025
(all amounts are expressed in RON, unless specified otherwise)

NOTE 9: Related parties (continued)

| Receivables | 31.03.2024 | 31.03.2025 |
|--------------------------------------|-------------------|-------------------|
| AO Ranbaxy Russia | 47,376,040 | |
| Ranbaxy Pharmacie Generique France | 496,672 | 457,409 |
| Ranbaxy Italy SPA | 768,961 | 400,482 |
| Sun Pharmaceutical Industries Ltd. | 18,261,577 | 30,550,504 |
| Sun Pharmaceutical Industries Europe | 1,819,658 | 1,896,410 |
| Sun Pharma UK Limited | | 390,035 |
| Sun Pharma Advanced Research Company | 589,374 | |
| Alkaloida Chemical Company Zrt. | 290,492 | |
| LLC "Ranbaxy Pharmaceuticals Ukraine | 3,478,874 | |
| Sun Pharmaceuticals Germany GmbH | 161,862 | 269,240 |
| Total | 73,243,510 | 33,964,080 |

| Collections | 31.03.2024 | 31.03.2025 |
|---|--------------------|-------------------|
| AO Ranbaxy Russia | 75,057,818 | 2,264,451 |
| Ranbaxy UK Limited | 784,361 | 659,443 |
| Ranbaxy Pharmacie Generique France | 2,909,424 | 2,646,750 |
| LLC Ranbaxy Pharmaceuticals Ukraine | 17,202,912 | 27,264,435 |
| Ranbaxy Italy Spa | 451,600 | 1,631,930 |
| Ranbaxy Spania | 113,743 | 241,247 |
| Sun Pharmaceutical Industries Europe BV | 13,333,069 | 15,041,156 |
| Sun Pharmaceutical Ltd. | 7,295,266 | 40,904,552 |
| Sun Pharmaceuticals Germany GmbH | 846,957 | 1,578,100 |
| RANBAXY (Poland) Sp. z o.o. | 48,889 | 41,526 |
| Alkaloida Chemical Company Zrt. | | 290,679 |
| Sun Pharma Advanced Reserch Company | | 580,408 |
| Total | 118,044,038 | 93,144,677 |

| Payments | 31.03.2024 | 31.03.2025 |
|---|--------------------|--------------------|
| Ranbaxy Poland Sp Zoo | 33,519,750 | 49,984,792 |
| Sun Pharmaceutical Industries Europe | 3,627,043 | 4,066,976 |
| Sun Pharmaceutical Industries Ltd. | 224,506,300 | 297,685,318 |
| Alkaloida Chemical Company Zrt. | 324,334 | |
| Sun Pharma(Netherlands)B.V | 825,150 | 862,210 |
| Taro Pharmaceutical Canada inc | | 204,155 |
| Aditya Acquisition Company Ltd. | 268,698 | |
| SUN PHARMA USA, Sun Pharma Holdings USA Inc (Previously known Ranbaxy Inc.) | 45,209 | |
| Total | 263,119,484 | 352,803,451 |

NOTE 10: Provisions

| Classification of provisions | | Balance at 31 March 2024 | Transfers | | Balance at 31 March 2025 |
|-------------------------------------|------------------------------------|---|-------------------|-------------------------|---|
| | | | To account | From account | |
| | 0 | 1 | 2 | 3 | 4 |
| 1 | Provisions for retirement benefits | 5,337,907 | 836,829 | 385,779 | 5,788,957 |
| 2 | Provisions for taxes | 9,103,205 | | 480,025 | 8,623,180 |
| 3 | Other provisions for expenses | 230.690 | | | 230,690 |
| Total | | 14,671,802 | 836,829 | 865,804 | 14,642,827 |

NOTE 10: Provisions (continued)

The provisions for retirement benefits increased with RON 451,050 mainly due to the increase of salaries.

The provision for taxes was built up according to the regulations in force (O.M.F.P 1802/2014) and is calculated based on the gross distributable and taxable reserves recognized in equity and the difference between the accounting net book value and the fiscal net book value of fixed assets. The provision amounts to RON 8,623,180 as at 31 March 2025.

NOTE 11: Investment subsidies

The Company has benefited in previous period by grants for fixed assets from the government and from the European Union.

The grants are recognized as income in the same time with the depreciation of fixed assets in connection with which they were received.

As of 31.03.2025 the information on subsidies recognized in the balance sheet is:

| Type of subsidies | Type of asset for which they were received | The initial value of the subsidy | The value in the balance sheet at 31.03.2025 | Remaining depreciation period (months) |
|--------------------------|--|----------------------------------|--|--|
| Government subsidies | Buidings | 892,500 | 66,196 | 21 |
| European Union subsidies | Buildings | 4,970,466 | 3,340,839 | 242 |
| | Plant and machinery | 5,546,348 | 184,878 | 4 |
| | Laboratory equipments | 217,611 | 3,602 | 4 |
| | Installations and machines | 983,519 | 829,844 | 81 |
| Total | | 16,610,444 | 4,425,360 | |

NOTE 12: Investments and sources of financing

As of 31 March 2025, share capital amounted to RON 24,993,398, and was divided into 249,933,981 fully paid shares with a nominal value of RON 0.1. Subscribed capital is fully paid.

NOTE 13: Profit appropriation

| Profit appropriation | 31.03.2024 | 31.03.2025 |
|--|--------------------|--------------------|
| 1.Profit of the year | 299,677,486 | 344,949,081 |
| 2.Profit distributed to reserves from tax facilities | | |
| 3.Profit not distributed (1-2) | 299,677,486 | 344,949,081 |

At the time of the preparation of the financial statements, no decision has been taken regarding the appropriation of the profit amounting to RON 344,949,081.

In accordance with the legal provisions, following the approval of the net profit distribution by the General Shareholders Assembly, it will be reported in the financial statements for the year 2026.

NOTE 14: Turnover

| | 31.03.2024 | 31.03.2025 |
|-----------------------------------|----------------------|----------------------|
| Net turnover out of which: | 1,271,280,392 | 1,419,608,363 |
| - domestic sales | 963,582,015 | 1,135,321,776 |
| - export sales | 307,698,377 | 284,286,587 |

The total net turnover was derived from sales made in the following countries:

| | 31.03.2024 | 31.03.2025 |
|-----------------|----------------------|----------------------|
| Romania | 963,582,015 | 1,135,321,776 |
| Russia | 69,993,841 | |
| Poland | 135,152,241 | 149,815,895 |
| India | 22,236,034 | 49,817,858 |
| Ukraine | 20,680,137 | 23,784,511 |
| Other countries | 59,636,124 | 60,868,323 |
| Total | 1,271,280,392 | 1,419,608,363 |

Net turnover comprises the amounts from sale of goods and rendering of services during the period 01.04.2024-31.03.2025.

Net turnover represents the sales less the discounts granted to the customers.

The net turnover was RON 1,419,608,363. As compared to the previous year, the net turnover has registered a growth of 11.67% in the context of the macroeconomic framework presented below.

Terapia operates in the market through the most important medicine distributors.

During 2025 the Company has developed and optimized marketing and selling activities together with new products launching.

NOTE 15: Operating result analysis

| Indicator | Previous year as at 31.03.2024 | Current year as at 31.03.2025 |
|--|--------------------------------|-------------------------------|
| 1 | 2 | 3 |
| 1. Net turnover | 1,271,280,392 | 1,419,608,363 |
| 2. Cost of goods sold and services rendered (3+4+5+6) | 484,418,478 | 512,216,457 |
| 3. Main activity expenses | 78,120,699 | 66,674,940 |
| 4. Cost of goods purchased | 321,884,627 | 353,340,671 |
| 5. Costs of sundry activities | 9,393,602 | 11,028,792 |
| 6. Indirect production expenses | 75,019,550 | 81,172,054 |
| 7. Gross profit (1 – 2) | 786,861,914 | 907,391,906 |
| 8. Research expenses | 11,264,529 | 11,972,670 |
| 9. Selling expenses | 256,716,494 | 295,685,788 |
| 10. General and administration expenses | 185,030,839 | 208,177,004 |
| 11. Other operating income | 3,728,683 | 1,783,041 |
| 12. Operating profit (7 – 8 – 9 – 10 + 11) | 337,578,735 | 393,339,485 |

NOTE 15: Operating result analysis (continued)

The Company includes under cost of goods sold the direct and indirect manufacturing costs as well as the utilities related to the manufactured production.

The costs related to research, selling, marketing and general administration are not included in production cost.

The cost of the goods sold also includes the adjustment regarding the transfer prices, in the sense of increasing costs, in the amount of RON 2,883,976, an adjustment made in connection with the goods supplied from Sun Pharmaceutical Industries Ltd India. The adjustment was necessary to comply with the principles of transfer pricing.

In order to compute the cost of goods sold, manufacturing costs are adjusted by taking into account the movements in stock during the year.

Research expenses, selling and marketing expenses and general administration expenses are not included in the manufacturing cost.

Selling expenses also include the movement in value adjustments of trade receivables.

The general administration expenses include the movement in the value adjustment of the stocks and other provisions.

The operating result increased in the current financial year compared to the previous year, mainly due to the increase in turnover.

NOTE 16: Information regarding the employees, the administrators and the directors

No advance payments or credits were granted to the administrators of the Company, in the reporting period.

| Average number of employees | 31.03.2024 | 31.03.2025 |
|--|-------------------|-------------------|
| Workers | 225 | 219 |
| Technical, economic and administrative personnel | 653 | 654 |
| Total | 878 | 873 |

| Number of employees | 31.03.2024 | 31.03.2025 |
|--|-------------------|-------------------|
| Workers | 236 | 227 |
| Technical, economic and administrative personnel | 683 | 673 |
| Total | 918 | 900 |

| Payroll expenses | 31 March 2024 | 31 March 2025 |
|---------------------------------|----------------------|----------------------|
| Gross salaries during the year | 141,385,291 | 155,630,427 |
| Lunch ticket expenses | 5,284,830 | 6,584,450 |
| Benefits in nature expenses | 1,022,195 | 1,041,249 |
| Insurance contribution for work | 3,091,267 | 3,486,891 |
| Preliminary salaries taxes | 14,712 | 39,195 |
| TOTAL | 150,798,295 | 166,782,212 |

NOTE 17: Leasing contracts

The Company has no financial leasing contracts at 31.03.2025.

The Company has operational leasing contracts with the following companies:

| Company | Contract | The object of contract | No, of used goods |
|----------------------------------|------------------------------------|-------------------------------|--------------------------|
| SC ARVAL SRL | Contract no. 11241 / 29.05.2012 | Vehicles | 240 |
| SC Porsche Mobility SRL | Contract no. 9112934 / 17.06.2014 | Vehicles | 57 |
| LeasePlan Romania SRL | Contract no. 100664/2 / 25.05.2018 | Vehicles | 58 |
| ETA automatizari industriale SRL | Contract no.194/18.06.2013 | GPS | 264 |
| SC ROXER GRUP SA | Contract nr. 3536 / 01.08.2021 | Echipamente xerox | 19 |
| SC GRENKE RENTING SRL | Contract nr.145-3157/25.09.2019 | Laptopuri | 196 |

Accounting of leases comply with applicable accounting rules and accounting policies of the Company.

NOTE 18: Other information

Information regarding the corporate income tax

The corporate income tax payable by the Company for the current year amounts to RON 56,068,095.

The legal tax rate in force is 16%. The effective tax rate for the period is 13.8 %, less than standard rate due to tax facilities that the Company has benefited from.

The Company had an accounting gross profit of RON 405,737,598 for the year ended 31 March 2025, a taxable profit of RON 433,482,260 and tax deductions in the amount of RON 13,289,067.

Also, in order to ensure an effective tax rate of 15% for the profit tax for the financial year ending on 31.03.2025, the rate required by the legislation on the minimum taxation of enterprise groups, established by Law 431/2023, the Company recognized in the profit and loss account a provision for profit tax of RON 4,720,422.

NOTE 18: Other information(continued)

The reconciliation between the accounting profit and the taxable profit is presented below:

| Crt. no, | Indicators | Row | 12 month period ended at 31.03.2024 | 12 month period ended at 31.03.2025 |
|-----------------|---|------------|--|--|
| 1 | Accounting profit before tax | 01 | 343,159,745 | 405,737,598 |
| 2 | Deductions out of which: | 02 | 38,954,896 | 21,819,436 |
| | - deductible tax depreciation and amortization | | 38,954,896 | 21,819,436 |
| | -deductible provisions | | | |
| 3 | Non-taxable income out of which: | 03 | 10,909,208 | 11,069,192 |
| | - other non-taxable income | | 10,909,208 | 11,069,192 |
| 4 | Non-deductible expenses out of which: | 04 | 75,166,825 | 60,633,290 |
| | - fines, taxes and penalties due to authorities | | | |
| | - sponsorship expenses | | 7,978,877 | 3,786,241 |
| | - non-deductible provisions | | 18,601,842 | 23,842,116 |
| | - accounting depreciation | | 42,931,259 | 25,527,874 |
| | - other non-deductible expenses | | 5,654,847 | 7.477.059 |
| 5 | Taxable profit (row 01 - row 02 – row 03 + row 04) | 05 | 368,462,466 | 433,482,260 |
| 6 | Total corporate income tax out of which: | 06 | 58,953,995 | 69,357,162 |
| | - corporate income tax at the rate of 16% | | 58,953,995 | 69,357,162 |
| 7 | Corporate income tax reductions calculated in accordance with applicable regulations | 07 | 15,471,736 | 13,289,067 |
| 8 | Corporate income tax due (row 06 – row 07) | 08 | 43,482,259 | 56,068,095 |
| 9 | Income tax related to previous years' rectifications | 09 | | |
| 10 | Income tax due (row 08- row 09) | 10 | 43,482,259 | 56,068,095 |
| 11 | Top up tax up to 15% effective tax rate | 11 | | 4,720,422 |
| 12 | Net accounting profit (row 01 - row 10 – row 11) | 12 | 299,677,486 | 344,949,081 |
| 13 | Tax payments made in advance, tax credit used, additional payment used | 13 | 45,914,646 | 58,604,777 |
| 14 | Income tax payable/ to be recovered (row 10 – row 13) | 14 | (2,432,387) | (2,536,682) |

The tax credit used to settle the profit tax is in the amount of RON 2,218,747.

At 31 March 2025, the Company have an unused fiscal credit in the amount of RON 109,374.

Other information

As of the balance sheet date, the Company has from Unicredit Bank Romania:

- a credit facility with amounting to EUR 5,500,000 unused as security for the issuance of letters of guarantee and for acreditivs;
- a facility of 4,000,000 EUR as a guarantee for Forex contracts;
- an over draft in amount of USD 20,000,000 for financing general needs.

NOTE 18: Other information (continued)

The unused credit facilities represent off balance sheet items and, consequently, are not reflected in the balance sheet of the Company as at 31 March 2025.

The amount paid for consultancy services during the period 01.04.2024-31.03.2025 amounts to RON 150,239 and relates to the following: legal consultancy, transfer pricing consultancy and tax consultancy

The financial activity generated a gain of RON 12,398,113 as shown below:

- net gain from exchange rate differences in the amount of RON 2,441,374, mainly due to the appreciation of the national currency against the foreign currencies;
- net gain interest in amount of RON 9,956,739 mainly generated from bank deposits.

NOTE 19: Analysis of main financial ratios

| FINANCIAL RATIOS | VALUE | VALUE |
|---|---|---|
| | 12 month period ended at 31.03.2024 | 12 month period ended at 31.03.2025 |
| 1. LIQUIDITY RATIOS | | |
| A. CURRENT LIQUIDITY RATIO – <i>index</i> - (current assets/current liabilities) | 3.66 | 1.89 |
| B. ACID TEST RATIO - <i>index</i> - (current assets - inventories/current debts) | 3.08 | 1.57 |
| 3. ACTIVITY RATIOS | | |
| A. STOCK TURNOVER - number of rotations (cost of sales / average inventory balances) | 3.41 | 3.50 |
| B. STOCK DAYS – days- (average inventory balances / sales cost x 365) | 107.02 | 104.21 |
| C. DEBTORS' DAYS–days- (average trade debtors' balances / turnover)*365 | 147.20 | 151.15 |
| D. RECEIVABLES TURNOVER - number of rotations (turnover / non-current assets) | 3.69 | 1.63 |
| E. TOTAL ASSETS TURNOVER - number of rotations (turnover / total assets) | 0.96 | 0.84 |
| 4. PROFITABILITY RATIOS | | |
| A. RETURN ON CAPITAL EMPLOYED % (profit before interest and corporate income tax / (equity +loan long term portion) | 33.02 | 32.46 |
| B. GROSS PROFIT MARGIN % (gross profit / turnover x 100) | 61.90 | 63.92 |
| 5. PROFITABILITY PER SHARE | | |
| A. EARNING PER SHARE - RON/ <i>share</i> (net distributable profit / weighted average number of ordinary shares) | 1.20 | 1.39 |
| Net distributable profit | 299,677,486 | 344,949,081 |
| Weighted average number of ordinary shares used in the calculations | 249,933,980 | 249,933,980 |

NOTE 20: Contingent liabilities

The Romanian Government has agencies authorized to perform controls of the companies which develop their activity in Romania. This controls are similar in nature with the tax controls performed by the tax authorities from the majority of the countries of European Union but can be extended not only to tax aspects but also to other legal aspects and regulations in the domains in which those agencies perform. It is probable that the Company will make the object of regular controls as new laws and regulations are issued.

The Company considers that all fiscal liabilities for the reporting period were recorded and presented in the financial statements.

Also, the Company has as at 31 March 2025 letters of guarantee amounting to RON 527,627 issued for the following:

- Italian-Romanian Industrial Development Enterprise - IRIDE SA the amount of 454,503 RON
- Italian-Romanian Industrial Development Enterprise - IRIDE SA the amount of 10,624 RON
- MINISTERUL APELOR SI PROTECTIEI MEDIULUI the amount of 30,500 RON
- DIRECTIA REGIONALA VAMALA CLUJ the amount off 30,000 RON

Capital commitments are in amount of RON 27,952,110 out of which RON 1,567,922 are related to expansion and improvement of constructions, RON 23,850,493 are related to production equipment, RON 1,579,018 are related to product licenses purchase, RON 505,760 are related to laboratory equipment and installations and RON 448,917 related to IT equipment.

During this financial year the Company has acquired the sales license for the Fibromun product from the company PHILOGEN S.p.A., from Italy. The intangible asset is disclosed under the licenses and trademarks caption both in the non-current assets table and in the balance sheet account. The Fibromun product is under trials for the treatment of advanced soft tissue sarcoma and glioblastoma.

The license agreement includes milestone consideration payments based on agreed parameters.

NOTE 21: Risk management

The following is a summary of the nature of activities and management policies with respect to risk management:

i) Foreign currency risk and inflation

The Company is exposed to currency risk through transactions that are denominated in currencies other than RON. The currencies giving rise to this risk are primarily the Euro, USD, PLN and Russian Ruble currencies.

In respect of monetary assets and liabilities held in currencies other than RON, the Company ensures that the net exposure is kept to an acceptable level on short-term by buying or selling foreign currencies at spot rates and where necessary, through forward operations.

NOTE 21: Risk management (continued)

The value of monetary current assets and current liabilities held in local and foreign currencies at 31 March 2025 can be analysed as follows:

| | RON | USD | EUR | Other currencies | Total |
|----------------------------------|--------------------|-------------------|--------------------|-------------------------|--------------------|
| Current assets | | | | | |
| Trade receivables | 596,988,811 | (12,908) | 20,023,172 | (1,670,544) | 615,328,531 |
| Other receivables | 19,505,576 | | | | 19,505,576 |
| Short-term investments | | 11,424,719 | | | 11,424,719 |
| Cash and cash equivalents | 17,533,341 | 34,913 | 2,663,462 | 4,423,857 | 24,655,573 |
| Total current assets | 634,027,728 | 11,446,724 | 22,686,634 | 2,753,313 | 670,914,399 |
| | | | | | |
| Current liabilities | | | | | |
| Loans and interest | | | | | |
| Trade payables | 78,679,974 | 2,748,956 | 214,160,607 | 25,661,821 | 321,251,358 |
| Other payables | 104,851,042 | | | | 104,851,042 |
| Total current liabilities | 183,531,016 | 2,748,956 | 214,160,607 | 25,661,821 | 426,102,400 |

ii) Interest rate risk

The Company has implemented a cash management policy to closely monitor unused funds and available credit facilities. Thus, the vast majority of interest-bearing assets as of 31 March 2025 include short-term financial investments. These assets have a variable interest rate. The credit line also has a variable interest rate.

iii) Credit risk

Management closely monitors its exposure to credit risk on a regular basis.

The Company used to cover the commercial risk an insurance policy of the commercial receivables and letters of bank guarantee issued by the customers in favor of the Company. As at 31.03.2025, the Company has covered the risk of non-payment for 98.2% of the balance of receivables on the domestic market.

The main customers of the Company are the large distributors of medicines operating in the Romanian market.

Over 72% of the Company's net turnover represents sales to the top 10 domestic customers of the Company, these being the main distributors on the Romanian market.

NOTE 22: Fundamental errors

During the period 01.04.2024-31.03.2025, the Company did not record any adjustments in the accounting records related to fundamental errors discovered in prior years' financial statements.

ADMINISTRATOR,
Dragoş Eugen Damian

ECONOMIC DIRECTOR,
Bucur Paul Cosmin